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ABSTRACT
HIV/AIDS is a disease of grave global importance with over 33 million people infected
world-wide and nearly 2 million deaths each year. The rapid emergence of drug resis-
tance, due to viralmutation, renders anti-retroviral drug candidates ineffectivewith alarm-
ing speed and regularity. Instead of targeting mutation prone viral proteins, an alterna-
tive approach is to target host proteins that interactwith viral proteins and are critical for
the HIV life-cycle. APOBEC3G is a host anti-HIV restriction factor that can exert tremen-
dous negative pressure by hypermutating the viral genome and has the potential to be a
promising candidate for anti-retroviral therapeutic research.
The work presented in this thesis is focused on investigating the A3G catalytic domain
structure and implications of various observed structural features for biological function.
High-resolution crystal structures of the A3G catalytic domain were solved using data
from macromolecular X-ray crystallographic experiments, revealing a novel intermolec-
ular zinc coordinating motif unique to A3G. Major intermolecular interfaces observed in
the crystal structure were investigated for relevance to biochemical activity and biologi-
cal function.
Co-crystallizationwith a small-moleculeA3G inhibitor, discoveredusinghigh-throughput
screening assays, revealed a cysteine residue near the active site that is critical for inhi-
bition of catalytic activity by catechol moieties. The serendipitous discovery of covalent
interactions between this inhibitor and a surface cysteine residue led to further biochem-
ical experiments that revealed the other cysteine, near the active site, to be critical for
inhibition.
Computational modeling was used to propose a steric-hinderance based mechanism
of action that was supported by mutational experiments. Structures of other human
APOBEC3 homologs were modeled using in-silico methods examined for similarities and
xv
differenceswith A3G catalytic domain crystal structures. Comparisons based on these ho-
mology models suggest putative structural features that may endow substrate specificity
and other characteristics to the APOBEC3 family members.
1Chapter I
Introduction
2Chapter I
Introduction
1.1 HIV
1.1.1 AIDS and Global impact
Human Immunodeficiency Virus (HIV), discovered in 1983 as the causative agent of Ac-
quired Immunodeficiency Syndrome (AIDS) (1–3), caused 1.8million deaths due to AIDS in
2009 and currently infects an estimated 33.3 million people globally with over 7000 new
infections per day or 2.8 million every year (4). The negative socioeconomic impact of
this epidemic has hit hardest the developing and underdeveloped countries, particularly
in Sub-Saharan Africa and Asia, extracting a substantial human price.
According to recent statistics, the incidence of new infections and fatalities from AIDS
is on a downward trend in countries with reasonable access to preventive and therapeu-
tic measures (4). Despite multi-billion dollar, multi-national efforts on education, pre-
vention, therapeutic management and research, numerous challenges remain. The most
significant being an absence of curative therapy due to rapid emergence of resistance to
drugs that target HIV proteins (5–9). Drug resistance arises primarily from viral mutation
patterns that lead to co-evolution of target viral proteins and their corresponding viral
interaction partners or substrates, while disrupting binding to drugs. Coupled with per-
sistence of latent HIV infection in host reservoir tissues, even in patients that may not
progress to AIDS, drug resistance leads to failure of anti-HIV therapy. Novel therapeutic
approaches, in order to remain effective, must be directed at targets that HIV depends on
for its life-cycle but, being host proteins, are incapable of mutating and thus contributing
to drug resistance (8, 10–13).
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1.1.2 Viral life-cycle
HIV, a lentivirus of the retroviridae family, is an enveloped, positive-sense, single-stranded
RNA virus (14, 15). The viral life-cycle may be broadly divided into six stages (Figure 1.1):
(i) Fusion and Entry into the host cell: HIV targets the host CD4+ T-cells, macrophages
and microglial cells. Entry is primarily mediated through interaction between the CD4
receptor and the gp120 subunit of the viral envelope glycoprotein (env or gp160). The
α-chemokine receptor CXCR4 and the β-chemokine receptor CCR5, individually or to-
gether, act as co-receptors mediating viral entry(16). gp120 binds to the CD4 receptor
with high affinity, subsequent binding with CXCR5/CCR5 co-receptor(s) trigger confor-
mational changes that expose the gp41 subunit of env that contains a “fusion peptide”
which is inserted into the host cell membrane. This insertion triggers a refolding of gp41
into an extended coiled-coil structure that assembles into a thermodynamically stable
six-helix bundle. The formation energy of this highly stable structure forces the viral
and host-cell membranes into close proximity, triggering a fusion of the two membranes
and through a series of intermediate states, leads to formation of a “fusion pore” that al-
lows the viral capsid to enter the host cell cytoplasm.
(ii)Uncoating andReverse transcriptionof the viral genomicRNA: Theviral capsid or core
is a conicalmacromolecular assembly, 100-120 nM long and 50-60 nMwide at the broadest
end. Nearly 1500 capsid monomeric subunits (CA) assemble into a fullerene cone formed
byhexameric and pentameric structural sub-assemblies that arise fromN-terminus-to-N-
terminus (NTD-NTD) and C-terminus-to-C-terminus (CTD-CTD) interactions. In addition
to the viral genomic RNA, it is comprised of CA (capsid) andNC (nucleocapsid), RT (reverse
transcriptase), IN (integrase), vpr (viral protein R) and numerous host proteins packaged
during viral assembly, such as APOBEC3G and Cyclophilin A. Reverse transcription of the
single-stranded viral genomic RNA to double-strandedDNA, a prerequisite for integration
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with the host genome, happens in the RTC (reverse transcription complex) composed of
the capsid proteins, RT and viral genomic RNA and/or newly reverse transcribing DNA.
The capsid is critical for delivering the RTC, also referred to as the PIC (pre-integration
complex) following uncoating and reverse transcription, to the nuclear pore. Successful
delivery of the uncoated, reverse transcribed viral genome to the nuclear pore is essential
for integration (11).
(iii) Nuclear import, Integration and Transcription: Prior to nuclear transport and in-
tegration into the host genome, the reverse transcribed viral cDNA is associated with a
tetramer of HIV integrase and other host proteins in the PIC. Other host proteins in the
PIC include factors that prevent auto-integration (BAF), compact viral cDNA (HMGA1) and
aid HIV integrase (LEDGF, hSNF5). The viral integrase is associated with LTR ends of the
viral cDNA and drives the ends into close juxtaposition with host DNA followed by inte-
gration via strand transfer reactions (17). The elongation of RNA transcribed from the
integrated viral genome is aided by binding of the HIV transcription transactivator pro-
tein Tat to the transactivating response region (TAR) in the newly transcribed RNA (18).
(iv)Nuclear export and Translation: The transcribed RNAmay be exported from the host
nucleus as unspliced (Gag, GagPol and genomic RNA), singly spliced (Env, Vif, Vpr, Vpu) or
doubly spliced (Nef, Rev, Tat). The HIV protein, Rev, plays the a critical role in the export
of unspliced RNA from the nucleus as it binds to the Rev response element (RRE) region in
the RNA and prevents splicing. Once exported, the spliced RNA is translated by the host
cellular machinery to viral proteins. The Gag and GagPol poly-proteins are precursors to
viral structural proteins and enzymes respectively, all essential to assembly, budding and
maturation of viral particles.
(v) Assembly, Budding and Maturation: The Gag poly-protein associates with the host
cell membrane and initiates assembly of viral components, including genomic RNA and
the ESCRT family of host proteins that are required for budding (TSG101, AIP1/ALIX) (15).
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The HIV structural proteins matrix (MA), capsid (CA) and nucleocapsid (NC) are derived
from the Gag poly-protein after cleavage by HIV protease (PR) following budding. This
cleavage of Gag and GagPol poly-proteins is essential for viral particle maturation and
subsequent host cell infection.
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Figure 1.1 : HIV life-cycle andhost anti-HIV factors (red boxes). Detailed discussionunder
Subsection 1.1.2 : Viral life-cycle and Section 1.2 : Host anti-HIV factors. Based on : ref.
(19).
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1.1.3 Pathogenesis and disease
HIV infects the target hosts through contact of viral inoculum with host mucosal sur-
faces such as during unprotected sexual intercourse, by transfusion of infected blood
(or derivatives such as plasma) and bymother-to-child transmission (MTCT) during preg-
nancy, parturition or breast feeding. CD4+ T-cells are the primary viral hosts in the ma-
jority of infections whereas memory T-cells are long-term reservoirs of transcriptionally
silent provirus. Initial acute HIV infection (acute retroviral syndrome) is characterized by
aflu-like viremiawithin 4 to 10 dayswith symptoms including fever, night sweats, arthral-
gia/myalgia, lymphadenopathy, nausea, vomiting, diarrhea and unexplainedweight-loss.
During this acute phase, viral load in the peripheral blood may be as high as 1 x 106/mL
to 10 x 106/mL. Most of the symptoms subside over 4 to 8 weeks as the viral infection
becomes clinically latent. Seroconversion is indicated by the detection of anti-HIV an-
tibodies by ELISA as the HIV p24 antigen drops to undetectable levels. The CD4+ T-cell
counts rebound but never approach pre-infection levels. On average, over the course of 8
to 10 years, the constant deterioration of the immune system (CD4+, CD8+ and other cells)
due to HIV replication, results in AIDS. The diagnostic criteria for AIDS include a deteri-
orating CD4+ count below 200/µL, emergence of opportunistic infections and neoplasms
and the appearance of syncytia-forming (SI) phenotypes of HIV (20).
1.1.4 Therapeutic approaches and Limitations
Therapeutic agents have adverse effects
The earliest class of therapeutic agents used for treating HIV infections were Nucleo-
side Reverse Transcriptase Inhibitors (NRTIs: Zidovudine/Azidothymidine, Didanosine,
Zalcitabine etc.) and Acyclic Nucleoside Phosphonates (Adefovir, Tenofovir, Cidofovir
etc.). These drugs were characterized by intolerance and severe adverse reactions due
to mitochondrial toxicity. Later, Non-Nucleoside Reverse Transcriptase Inhibitors (NNR-
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TIs: Nevirapine, Efavirenz etc.), that bind non-competitively to RTwere developed. These
drugs had fewer side-effects than NRTIs but caused complications such as skin rashes and
hepatotoxicity. Protease inhbitors (PIs: Saquinavir, Ritonavir, Nelfinavir, Darunavir etc.),
target HIV protease and disrupt viral maturation. PIs are potent inhibitors of the hepatic
cytochrome P450/CYP3A4 enzymes and can cause severe drug interaction issues. Other
complications include PI associated lipodystrophy, hepatic transaminase elevation and
sensory neuropathy (20).
Major limitations of therapeutic agents
Three classes of drugs mentioned above, NRTIs, NNRTIs and PIs, have been the backbone
of Highly Active Anti-retroviral Therapy (HAART) in combination with the newer inte-
grase and entry inhibitors discussed below. However, in addition to adverse effects, the
greatest challenge to their efficacy and use arises fromdrug-resistance. Drug resistance, a
change inmolecular recognition, is caused bymutations in theHIVgenome that occur as a
result of error-prone reverse transcription by RT and possibly by the action of APOBEC3G,
a cellular cytidine deaminase causing viral genomic G-to-A hypermutations(21). These
mutations cause structural changes in the drug targets, such as HIV protease, that lead to
a reduction or loss of binding/affinity to the drugmolecule(s) without significant changes
to the target’s biological activity (22–25). Mutations in the drug target (protease) may be
accompanied by mutations in the viral substrates (Gag/GagPol), a phenomenon referred
to as “co-evolution” that derails drug binding while allowing normal or near normal tar-
get/substrate interaction (26, 27).
Recent anti-HIV drugs are targeted at HIV integrase/IN (Raltegravir), HIV gp41 (Enfu-
virtide), HIV Gag protein (Bevirimat) or the host cell CCR5 receptor (Maraviroc) with the
aim to minimize adverse effects and mitigate drug resistance (7, 28, 29). However, drug
resistance has emerged rapidly in almost all cases, sometimes even during early phases of
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clinical trials. This rapid emergence of drug resistant virus populations quickly renders
ineffective anti-retroviral drugs, resulting in an absence of a curative treatment.
1.2 Host anti-HIV factors
During the course of viral life-cycle, HIV interactswith numerous host proteins to subvert
the cellular machinery and pathways to its advantage (28). Some of these host proteins
exert a deleterious effect on HIV and have evolved as “restriction factors” against retro-
viruses. The virus attempts to evade or degrade these proteins during replication using
viral and other host proteins. Given the rapid emergence of drug resistance amongst vi-
ral proteins, these host factors are crucial therapeutic targets that may be leveraged by
enhancing their activation or reducing their HIV driven degradation, in principle, with-
out risking emergence of drug resistance. The principal host targets in this regard are
the tripartite motif protein TRIM5α, interferon induced protein BST-2/Tetherin, cellular
miRNAs and the cytidine deaminases APOBEC3G/3F discussed below.
TRIM5α
TRipartite Interaction Motif-containing 5 isoform alpha is a human cytoplasmic protein
that as a part of the anti-retroviral innate immune response inhibits HIV infection (30–
32). TRIM5α has been shown to act by sensing the hexameric viral capsid lattice, much
like a pattern recognition receptor (PRR), binding to it and causing its accelerated disin-
tegration during viral entry (33, 34). This rapid uncoating of the viral genome disrupts
RT activity effectively preventing generation of proviral DNA (35).
BST-2/Tetherin
Bonemarrow STromal cell antigen 2, a membrane targeted innate immune response pro-
tein, was recently discovered to adversely impact virionbudding, an effect thatwas demon-
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strated to be negated by the viral vpu protein (36). The budding virions appear unable to
detach from the host cell membrane and/or each-other due to the “simple and direct”
effect of BST-2, also known as “Tetherin” as it tethers the virions to the infected host cell
(37, 38).
Cellular miRNAs
MicroRNAmolecules (miRNAs) are 19-25 nucleotide long, single stranded RNAmolecules
that play a critical role in the regulation of cellular protein expression and function (39,
40). Recent evidence shows they may play important roles in regulating HIV infection
directly by acting against HIV nef (miR-29a) or indirectly by repressing cellular Cyclin T1
(miR-198) to decrease viral infectivity (41–45).
1.2.1 APOBEC proteins
TheAPOBECproteins arenamedafter thefirstmember of the familyAPOBEC1or “apolipopro-
tein B mRNA editing enzyme, catalytic polypeptide #1”, a cytidine deaminase responsi-
ble for post-transcriptional modification of the apolipoprotein B mRNA changing a CAA
codon into a stop codon (46, 47). Othermembers of this family inhumans includeAPOBEC2,
APOBEC3 (seven subfamily members: A, B, C, D/E, F, G and H) and APOBEC4, all charac-
terized as cytidine deaminases (48–50).
A short note on cytidine deaminases
Deaminases are a class of enzymes found in fungi, archea andmetazoa that act on free nu-
cleosides or nucleotides (cytosine/cytidine) or on polynucleotide sequences containing
adenines: such asADAR (AdenosineDeaminaseRNA-specific) that acts ondouble stranded
RNA or ADAT (Adenosine Deaminase t-RNA specific) that acts on tRNA. Similar enzymes
acting on cytidines in polynucleotides are AID (Activation Induced Deminase) that acts
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on DNA and APOBECs (Apolipoprotein-BmRNA-Editing Catalytic Polypeptide) that act on
RNA/DNA. The defining characteristic of these enzymes is the presence of one or more
[H/C]XE and PCXXC motifs that coordinate a zinc atom at the enzyme active site (51), al-
though exceptions exist (52). Antibody class switch recombination and IgGdifferentiation
result from the action of Activation InducedDeaminase (AID) (53, 54)with recent evidence
also suggesting a role in DNA demethylation and epigenetic control (55). APOBEC3 pro-
teins help defend against retroviruses such as HIV (A3G) and DNA viruses like AAV (A3A)
(56, 57). Adenosine Deaminases Acting on RNA or ADARs convert adenosine to inosine
in host and virus encoded double stranded RNA molecules that is read as guanosine and
thus modulate protein expression and activity 58. ADATs (Adenosine Deaminase Acting
on tRNA), on the other hand are known to act on the wobble position of tRNAAla:34 and
may be required for cell cycle regulation (59).
Cytidine deaminases have been the focus of various drug development efforts over the
years. Human cytidine deaminase (hCDA) was one of the earliest targets to be investi-
gated because it was shown to degrade the anticancer drugs cytosine arabinoside and
5-azacytidine (60–63). Non-mammalian cytosine deaminases, in combination with small
molecules such as 5-fluorocytosine, have been investigated as suicide inhibitors for use
in anti-cancer gene therapy efforts (64). Recent discoveries of AID and APOBEC proteins
and their potential for generating cancer and autoimmune disorders by indiscriminate
cytidine deamination in the genome has focused interest on them (65–69). APOBEC3G,
as described later, is of great interest in the pathophysiology of HIV infection as it in-
hibits the virus by cytidine deamination and is itself targeted by the HIV vif protein for
degradation via the host cell proteasome pathway (19, 70–76).
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The cytidine deamination reaction
The cytidine deamination reaction plays an integral role in the immune system. Cytidine
deamination refers to the biochemical conversion of a (deoxy)cytidine (dC/C) into a (de-
oxy)uridine (dU/U) by enzymatic means. This conversion primarily occurs in the context
of single stranded polynucleotides (DNA/RNA), but may also act on other substrates such
as cytosine nucleoside analogs (60–63). The deamination reaction may be represented
as a six step process that requires, in addition to the enzyme and substrate, one water
molecule and releases one molecule of ammonia (deamination) per reaction (77, 78). The
reaction starts with nucleophilic attack by the zinc hydroxide oxygen at C4 ring position
of the bound substrate dC/C, followed by protonation of theN3 ring nitrogen byOE1 of the
catalytic Glu residue, resulting in formation of the first tetrahedral intermediate. Proton
transfer from the zinc activated hydroxyl group to the leaving NH−2 group via OE2 of the
catalytic Glu results in formation of the second tetrahedral intermediate. Following this
step NH3 escapes, leaving behind the enzyme-product complex that, after releasing the
product dU/U, accepts a new water molecule that is deprotonated by the Glu carboxylate
group and binds the Zn atom. A new substrate dC/C may now enter the active site (and
the reaction cycle repeats) (Figure 1.2).
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Figure 1.2
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Figure 1.2 : Cytidine deamination in six steps: (1) Enzyme-Substrate complex (deoxy-
cytidine). Glu is the catalytic glutamate residue (E259 in A3G), Zn is the active site zinc
atom (coordinated by two Cys and one His in A3G). (2) First tetrahedral intermediate. (3)
Second tetrahedral intermediate. (4) Enzyme-Product complex (deoxyuridine). (5) New
water molecule approaches the active site. (6) New substrate molecule enters the active
site. Based on : ref. (77, 78).
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hCDA and the AID/APOBEC family
hCDA — The human cytidine deaminase gene is located on chromosome 1 and an evo-
lutionarily conserved member of the pyrimidine salvage pathway. In addition to acting
on cytidine, hCDA acts on nucleoside-analogue anti-viral and anti-cancer agents thus an
important drug target for inhibitory adjuvants (60). Metabolism of anti-cancer agents by
hCDA is also being explored as a means to alleviate the toxic effects of these agents on
myeloid stem cells by using hCDA as a transgene via gene therapy approaches (79).
AID — The Activation Induced Deaminase expressed by the Activation Induced Cyti-
dine Deaminase (AICDA) gene locus on chromosome 12 in humans, has been extensively
investigated for its role in antibody diversification by somatic hypermutation (SHM) and
class switch recombination (CSR) (54, 80). Recent investigations into AID function reveal a
role in DNA demethylation driven epigenetic reprogramming by deamination of methyl-
cytosines (81, 82).
APOBEC1 — The APOBEC1 protein, encoded by a gene locus on chromosome 12, was
the first polynucleotide cytidine deaminase to be identified (47, 83). APOBEC1 edits the
apolipoprotein B mRNA transcript by deaminating the cytidine at position 6666, con-
verting a CAA codon into a stop codon, leading to production of truncated form of the
apoB lipoprotein called apoB48 that is required for lipid transport in chylomicrons (84).
Non-human APOBEC1 proteins may be involved in DNA cytidine deamination and de-
fense against hepadnavirus (mHBV) infections (85). Additional evidence points to DNA
demethylation activity in vertebrates (82, 86)
APOBEC2— Expressed specifically in cardiac and skeletal muscles (49), APOBEC2 is en-
coded by a gene locus on chromosome 6 and although no DNA or RNA editing activity has
been ascribed, APOBEC2 has been demonstrated to be essential for muscle development
and maintenance in mice models (87) and play a role in vertebrate DNA demethylation
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(86).
APOBEC3— The APOBEC3 sub-family of proteins are encoded by a gene locus on chro-
mosome 22 and discussed in the next section.
APOBEC4—Bioinformatics methods have predicted the existence of an APOBEC4 gene
locus on chromosome 1, however no functional significance has been ascribed to it as yet
(50).
APOBEC5 — The existence of a new member of the APOBEC family, APOBEC5, was
recently predicted by bioinformatics approaches in reptilian genomes (88) and demon-
strated by experimental means in the bacterium Xanthomonas oryzae (89, 90). The pres-
ence and significance of this enzyme in mammals in general and humans in particular is
as yet unknown.
The APOBEC3 sub-family
The APOBEC3 genes exist only in mammals (absent in mice), preferentially deaminate
cytidines in DNA (91) and appear to have arisen as a result of tandem gene duplication
events (92, 93). Chromosome 22 (locus q13.1) carries all seven human APOBEC3 genes
enclosed between the genes CBX6 and CBX7 that are conserved in all vertebrates. The
defining characteristic of all APOBEC3 genes is the presence of one or two “Z-domain”
sequences carrying residues necessary for coordinating zinc and essential to deamination
activity and/or substrate binding. The Z-domains may be classified by their signature
sequences and represented schematically as in Figure 1.3 (94, 95).
Human APOBEC3A, 3C and 3H contain one Z-domain each, Z1, Z2 and Z3 respectively,
whereasAPOBEC3B (Z2-Z1), 3D/E (Z2-Z2), 3F(Z2-Z2) and 3G (Z2-Z1) contain twoZ-domains.
The Z-domain signatures do not signify the presence or absence of catalytic capability, or
domain preponderance, for example, the N-terminal Z2 domain in APOBEC3G is deami-
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nation incompetent whereas the Z2 domain located C-terminally in APOBEC3F is capable
of cytidine deamination (96). Similarly, APOBEC3B has a N-terminal Z2 and a C-terminal
Z1 domain and both are catalytically active (97).
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Figure 1.3 : A schematic representation of the three Z-domain signature sequences in
APOBEC3 proteins (Z1: green, Z: orange and Z3: blue). CBX6 and CBX7 genes flank the
APOBEC3 locus on chromosome 22. The catalytically active domains are indicated by
the@ sign and residues that uniquely identify each domain are enclosed in highlighting
boxes. Based on : ref. (94, 95).
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1.2.2 APOBEC3G
HumanAPOBEC3G (A3G), also called CEM15, is a cytidine deaminase discovered to exert an
anti-retroviral effect against HIV in 2002 (57). HIV virions lacking the viral protein, vif,
were demonstrated to be capable of infecting and replicating in “permissive” cell lines
that lacked CEM15 (CEM-SS, Sup-T1 and 293T). Not only did the “non-permissive” cell
lines (CEM, H9 and HUT78) not allow successful infection or replication of the Δvif HIV
virions but expressing CEM15 in the “permissive” cells was sufficient for making them
“non-permissive”. Further investigation revealed that HIV vif (virion infectivity factor)
binds to A3G and targets it to the proteasomal pathway for degradation (72, 98–103), by
hijacking the Cul5-E3 ring ligase complex (76). Vif directed proteasomal degradation of
A3G greatly reduces the number of A3G molecules packaged into assembling virions thus
abrogating A3G’s anti-retroviral effect during subsequent host cell infection (104).
A3G : mode of action
Expression of A3G in response to HIV infection was recently demonstrated to result from
stimulation of TLR3 (Toll Like Receptor 3), a pattern recognition receptor (PRR) of the in-
nate immune system that is expressed on dendritic cells and senses double stranded RNAs
generated during retroviral replication. In addition to stimulating A3G expression, the
downstream NF-κB and IRF3 driven Type-I Interferon (IFN-α/β) signaling also increased
Tetherin and anti-HIVmiRNA expression, further accentuating the viral restriction effect
(105).
A3G is known to exist intracellularly as high molecular mass (HMM) and low molec-
ular mass (LMM) ribonucleoprotein complexes. The HMM form is associated with RNPs,
Staufen granules, Alu and hY RNAs and although enzymatically inactive, is shown to re-
strict Alu retrotransposons (106). RNAse action can convert the HMM form to enzymati-
1.2. HOST ANTI-HIV FACTORS 22
cally active LMM that is responsible for anti-HIV activity (107). The LMM formmay arise
from disintegration of HMM complexes or by translation of fresh A3G transcripts in the
cytoplasm and may then become associated with cell membrane lipid-rafts. This raft-
associated LMM form was recently shown to be the primary method of packaging A3G
into newly assembling HIV virions (108).
HIV encapsidatedA3G is released into thehost cells infected by the virion and by virtue
of being closely associatedwith the viral genomic RNA is believed to have favorable access
to the newly reverse transcribed DNA (109–113). The exact mechanism(s) for the anti-
HIV effect of A3G are under dispute in the present literature (114–125) with the primary
contention being the requirement of cytidine deaminase activity for exerting the anti-
HIV effect. However, the general consensus remains that A3G is capable of exerting an
anti-HIV effect and vif attempts to thwart A3G by targeted degradation.
A3G enzymatic activity has been demonstrated to be “processive”, meaning, the en-
zyme does not release the substrate untilmultiple catalytic reactions have occurred, how-
ever it may change substrate polynucleotide strands by “intersegmental” transfer (126).
A3G prefers a “signature” sequence 5’-CCC for binding and deaminating within substrate
polynucleotides in a 3’ 5’ direction, preferentially deaminating the underlined C. (127–
130)
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Figure 1.4 : APOBEC3G (A3G) activity in context of the HIV life-cycle. A3G (filled blue
ellipses) is present in the cytoplasm as either a High-Molecular-Mass (HMM), primarily
dormant form, or as Low-Molecular-Mass (LMM) form that is capable of restricting HIV.
The viral vif protein (yellow), expressed in the host cell after viral genomic integration,
targets A3G to the cellular proteasomal degradation pathway and attempts to thwart its
packaging into the newly assembling virions at the cell memebrane. However, if A3G
gets packaged into the assembling virions, it is capable of restrictiong viral replication by
cytidine deamination when the virions infect the next host cell. Based on : ref. (131).
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A3G and Vif
The virion infectivity factor (vif) is a 192 residue (23kD) non-enzymatic HIV protein that
is predicted to be intrinsically disordered (132, 133) and leads to A3G degradation us-
ing the host-cell proteasomal machinery (76). Intrinsically disordered proteins (or, na-
tively unstructured proteins) are characterized by a lack of well-defined tertiary struc-
ture amongst other features (134). Vif is predicated to posses a highly disordered C-
terminus that, like most intrinsically disordered proteins, assumes a more ordered state
upon oligomerization or in a complex with binding partners (135, 136). The intrinsic dis-
order creates unique challenges for structural analysis of vif and as of yet no full-length
solution/NMR or crystal structures have been solved (137). However, experimental evi-
dence accumulating over the previous decade has identified various features of vif that
are involved in proteasome mediated degradation of A3G.
The Cullin5-Ring-Ligase (CRL5) complex is a E3 ubiquitin ligase, composed of the scaf-
fold protein Cullin5, RING-finger protein Rbx2/ROC2, the adapter proteins Elongin B and
C and a “substrate recognition protein” that targets the actual “substrate protein” to
this complex (Figure 1.5). The “substrate protein” is ubiquitylated by an E2 ubiquitin-
conjugation enzyme that also binds CRL5 (138). CRL5 recognizes a “SOCS-box” (Suppres-
sor Of Cytokine Signaling) motif in the “substrate recognition protein”, also present in
HIV vif, that allows it to bind the CRL5 complex and present A3G for ubiquitylation (137,
139). Recent evidence suggests cellular protein CBFβ (core binding factor, beta subunit)
maybe involved in binding of vif to CRL5 (CSHL, Retroviruses 2011meeting). Other studies
suggest vifmay inhibit A3Gactionwithout proteasomal degradationbynon-competitively
binding to substrate bound A3G and interfering with its catalytic activity (140, 141).
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Figure 1.5 : A schematic representation of the Vif-Cullin5-RING-Ligase complex. Vif
interacts with Elongin B/C as well as Cul5 via the C-terminal domain, whereas the N-
terminal domain binds APOBEC3G and drives it to close proximity with the E2 ubiquitin
ligase for poly-ubiquitylation. Based on : ref. (142).
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A3G structures and implications for HIV
Currently, three NMR solution structures (PDB: 2JYW, 2KBO, 2KEM) and two X-ray crys-
tallographic structures (PDB: 3E1U/3IQS, 3IR2) of the A3G C-terminal domain (CTD) are
available from the Protein Data Bank (PDB/RCSB) (143–147) (Figure 1.6). The CTD is the
catalytically active domain in A3G and the NTD, although containing a zinc-binding site
(Z-domain), is catalytically inactive and is required for effectively binding the substrate
polynucleotide sequence (148). The A3G NTD is predicted to be intrinsically disordered
(149), as compared to the CTD, and may be a contributing factor to the challenges faced
during soluble overexpression and purification of full-length A3G required for NMR struc-
ture solution or X-ray crystallography efforts.
The earliest A3G structure to be deposited in the PDB was the NMR solution structure
(2JYW : 143) of the A3G-CTD, residues 198-384, with five solubility enhancing mutations,
L234K, C243A, F310K, C321A and C356A that were elucidated earlier as not having any
deleterious effect on enzymatic or biological activity (150). This solution structure es-
tablished and corroborated features predicted from previous experiments, such as the
arrangement of active residues that coordinate a zinc atom and secondary structure con-
tent of helices, sheets and loops. The X-ray crystallographic structure of the wild-type
A3G-CTD residues 197-380 (3E1U : 146), with the last four residues truncated, was pub-
lished the same year and confirmed the active site zinc coordination geometry as well as
most secondary structure features observed in the NMR solution structure. Two struc-
tural features, a putative substrate binding “groove” and a large loop (AC loop 3 per the
authors), were in dispute between the two structures. Another NMR solution structure
(2KBO : 144) of a slightly longer construct (residues 193-384) and subsequent modeling
and experimental evidence (70) attempted to reconcile the differences in substrate ss-
DNA strand binding orientation, suggested by the previous structures, by introducing a
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third putative substrate orientation. Similarly, the question of the AC loop 3 shape could
not be resolved from the myriad of orientations observed in solution. However, the au-
thors demonstrated a 3’ 5’ order of cytidine deamination by A3G using time-chase 1H
NMR spectroscopy, corroborating previous observations in the literature (127–130). The
question of (AC loop 3) structure was settled by the next NMR solution structure (2KEM
: 145) of the A3G-CTD spanning residues 191-384 and incorporating the five solubility
enhancing mutations enumerated earlier. The authors used NOE measurements to ar-
rive at the distances between carbonyl oxygens and amide nitrogens of the polypeptide
backbone in solution and confirm the arrangement of residues within the β2-β2′ “bulge”
(author terminology). In addition, the authors also proposed a full-length A3G model
with the A3G-NTD homology modeled from the existing CTD structures and some of the
inter-domain linker region residues (191-196) now resolved in this structure. Our A3G-
CTD structure in the PDB (3IR2 : 147) is the second X-ray crystallographic structure of
A3G-CTD to be solved and it highlighted various errors in the previous crystal structure
(3E1U), prompting a revision of the structure coordinates from the authors (3IQS : under
same reference as 3E1U). A novel, inter-molecular, zinc binding site was also observed in
this (3IR2) structure; further details are discussed in the next chapter of this dissertation.
The absence of a high-resolution full-length A3G structure or co-structure with sub-
strate or inhibitors leaves open numerous questions regarding oligomerization, binding
to vif (occurs at the NTD), substrate orientation at the active site and structural features
pertinent to anti-HIV activity. Various models have been put forward in an attempt to
answer some of the questions enumerated above and tested using different experimental
methods. The veracity of such models may well be confirmed once reliable structures in-
cluding the A3G NTD or co-structures with vif or polynucleotide substrates become avail-
able. However, the structural data available to date have helped answer some very impor-
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tant questions such as A3G active-site architecture and putative A3G-CTD oligomerization
interfaces, with direct implications for anti-HIV therapeutic approaches.
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Figure 1.6 : A schematic representation of the various A3G C-terminal domain constructs
that have been used for structure elucidation. The full-length, wild-type, A3G is drawn
at the top, followed by the CTD constructs. The PDB IDs of structures for each construct
are listed within square brackets. Solubility enhancing mutations, L234K, C243A, F310K,
C321A and C356A are indicated by vertical bars and letters K/A. Based on data from refs.
(143 – 2JYW), (144 – 2KBO), (145 – 2KEM), (146 – 3E1U/3IQS), (147 – 3IR2).
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1.3 Scope of the thesis
HIV/AIDS is a disease with extensive global impact and the search for curative treatment
has proved to be a challenge despite intensive research, in large part due to viral muta-
tions that lead to drug resistance and eventual failure of anti-retroviral therapy. Exclu-
sively targeting HIV proteins for anti-retroviral drug discovery will, in all likelihood, pose
the same problem. The complementary approach is to investigate viral-interacting host-
cell proteins and disrupt protein-protein interaction(s) that are critical to viral life-cycle.
A representative example is the interaction between HIV Vif and human APOBEC3G pro-
teins, wherein, Vif binds APOBEC3G and targets it for proteasomal degradation. Why?
Because APOBEC3G, a cytidine deaminase, is capable of hypermutating the viral genome
to the detriment of HIV. In attempting to get rid of A3G, Vif has to hijack the host cell ma-
chinery and bind not only A3G, but also various other proteins that form the Cul5-RING-
E3 ubiquitin ligase complex. Presently, the absence of any high-resolution structures of
Vif preclude it being considered as a feasible target for anti-retroviral drug discovery ap-
proaches. Given the history of rampant and rapid emergence of drug resistance, Vif ap-
pears to be an even less attractive drug target, whereas, host proteins, being immutable,
are far better candidates for the future of anti-HIV therapeutic research.
It is pertinent to mention here that two seemingly opposite schools of thought exist
vis-a-vis the approach to A3G as an anti-HIV target:
— the ’activation’ school of thought argues for approaches that will increase A3G activity
in host cells to restrict HIV infection
— the ’inhibition’ school suggests that inhibiting A3G activity may be of benefit in pre-
venting sub-lethal mutagenesis that may potentially inflate the library of mutations in
the HIV genome that allow the virus to escape therapeutic agents – thus causing drug re-
sistance. Proponents of this school also point out the dangers to host genome from A3G
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activation and unchecked cytidine deamination activity that may lead to erratic muta-
tions and eventually carcinomas.
Both schools of thought have valid points favoring their respective approaches and the
ideal approach may well lie in the middle, with neither unchecked activation, nor total
inhibition but a well orchestrated ’modulation’ of A3G action.
Chapter II : Crystal structure of theAPOBEC3Gcatalytic domain reveals potential oligomer-
ization interfaces : The work presented in this chapter attempts to explore and under-
stand the structural details of the A3G catalytic domain, important for the anti-HIV effect
exerted by full-length A3G in the host cell, by solving a high-resolution crystal structure.
Various structural features observed in the crystal structure are discussed and results
from experiments designed to interrogate the relevance of these structural feature to
A3G function and anti-HIV activity are presented.
Chapter III : First-in-class small molecule inhibitors of the single-strand DNA cytidine
deaminase APOBEC3G : This chapter describes the results of efforts to discover novel
small-molecule ligands thatmay bind A3G and interfere with its cytidine deamination ac-
tivity. A High Throughput Screen (HTS) was developed to assay the activity of compounds
from a small, commercially available library and the best candidate compoundswere used
for co-crystallization with the A3G catalytic domain described earlier. Serendipitously,
one co-crystal structure could be solved with a compound that bound covalently to a sur-
face cysteine residue. Further investigation revealed the critical cysteine to be the one
located near the active site and not the one on the surface. The cysteine required by the
compound to exert an inhibitory effect had beenmutated to an alanine residue in the con-
struct used for co-crystallization during earlier attempts at improving protein solubility.
Results from experiments designed to validate the above are described and discussed in
this chapter. Numerous high-resolution crystal structures were solved over the course of
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attempts at co-crystallization with A3G inhibitors, including an “apo” crystal structure,
with the inhibition critical cysteine restored, that is presently the highest resolution crys-
tal structure of the human A3G catalytic domain. In the absence of a co-crystal structure
with the relevant cysteine residue, in-silicomodelingwas used to propose a putativemech-
anism of action arising from steric hinderance at the active site.
Chapter IV : Comparative analysis of Z-domain signature proteins in the human APOBEC3
subfamily : The availability of high-quality, high-resolution structural data for a protein
enablesmodeling of relatedhomologswith reasonable confidence. This chapter describes
an attempt at in-silico homology modeling of some APOBEC3 subfamily proteins based on
the high-resolution crystal structures of A3G catalytic domain. Similarities and difference
across the models are discussed in light of data available in the current literature.
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2.1 Abstract
APOBEC3G is a DNA cytidine deaminase that has antiviral activity against HIV-1 and other
pathogenic viruses. In this study the crystal structure of the catalytically active C-terminal
domain was determined to 2.25Å. This structure corroborates features previously ob-
served in nuclear magnetic resonance (NMR) studies, a bulge in the second beta strand
and a lengthening of the second alpha helix. Oligomerization is postulated to be critical
for the function of APOBEC3G. In this structure, four extensive intermolecular interfaces
are observed, suggesting potential models for APOBEC3G oligomerization. The structural
and functional significance of these interfaceswas probed by solutionNMRanddisruptive
variantswere designed and tested for DNAdeaminase and anti-HIV activities. The variant
designed to disrupt the most extensive interface lost both activities. NMR solution data
provides evidence that another interface, which coordinates a novel zinc site, also exists.
Thus, the observed crystallographic interfaces of APOBEC3G may be important for both
oligomerization and function.
2.2 Introduction
APOBEC3G (A3G), a DNA cytidine deaminase, belongs to the larger APOBEC family of pro-
teins. Members include activation induceddeaminase (AID), APOBEC1, APOBEC2, APOBEC4,
and, in addition to A3G, six APOBEC3s (A3s), (48, 51, 92, 93); reviews by: (116, 120, 142,
151–153). These proteins have diverse biological functions that include editing mRNA
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(APOBEC1), diversifying antibody gene DNA (AID), and restricting the mobilization of
retroviruses and retrotransposons (A3s).
All the A3s (A, B, C, DE, F, G, andH) are single-strandDNA cytidine deaminases known to
inhibit multiple retroelement substrates. The deaminases possess either one or two con-
served zinc-coordinating (Z)motifs, with the consensus amino acid signature, Hx1Ex24−28PCx2−4C
(48, 67, 94, 95). Zinc coordination is mediated by a histidine and two cysteines. The hy-
droxide that subsequently converts cytidine to uridine (C-to-U deamination) is generated
when the active site glutamate removes hydrogen from water.
HIV-1, the retrovirus that causes AIDS, is the most prominent pathogen restricted
by A3G (57, 117, 154–156). A3G suppresses HIV-1 infectivity by entering viral particles
and deaminating the viral cDNA cytidines to uridines during reverse transcription. The
uridines introduce adenosines in the complementary genomic strand which are often de-
tected as the hallmark G-to-A hypermutations. Thesemutations produce stop codons and
amino acid changes that can ultimately inactivate the virus. However, HIV-1 efficiently
counteracts restriction by A3G, with the viral Vif protein binding and targeting the cyti-
dine deaminase for proteasomal degradation; reviews by: (120, 142, 151, 153).
The life-or-death interaction between human A3G and HIV-1 Vif has made A3G the
prototype member of the APOBEC family for biochemical and structural investigations.
A3G has two consecutive Z-motifs giving the sequence of the enzyme an internal pseudo-
symmetry. In the past two years, significant advances have been made in elucidating the
structure of the C-terminal catalytic domain of A3G (A3G-CTD) but the conformations of
several important functional regions differ between three NMR structures and a single
X-ray crystal structure (143–146). The present study aims to resolve some of the contro-
versy by determining a new, higher-resolution crystal structure of A3G-CTD. This new
structure differs from the recently reported crystal structure (PDB ID: 3E1U with R-factor
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25.2%, R-free 26.7%, Resolution 2.3Å) and strongly supports the structural integrity of the
NMR structures (PDB IDs: 2JYW, 2KBO, 2KEM). Most importantly, this new crystal struc-
ture reveals four extensive interfaces, of which one or more may be important for A3G
oligomerization and biological activity.
2.3 Results
The crystal structure of thehumanAPOBEC3G catalytic domain, A3G191-384-2K3A–where
2K3A is L234K, C243A, F310K, C321A and C356A (145) – was determined at 2.25Å resolu-
tion. The A3G191-384-2K3A crystal structure was solved bymolecular replacement, using
a highly truncated model based on (PDB ID: 3E1U) (146). The crystal structure contains
two molecules of A3G191-384-2K3A in the asymmetric unit. The final refinement statis-
tics are: Rfactor (Rfree) 16.57% (20.82%) (Table 2.1).
The crystal structure of A3G191-384-2K3A has a core α-β-α fold consistent with other
cytidine deaminases (143, 146, 157). As seenwith the other A3G-CTD structures (145, 146),
this structure has a five-stranded β-sheet surrounded on both sides by six α-helices (Fig-
ure 2.1). Secondary structural elements are numbered after the A3G191-384-2K3A NMR
structure (PDB ID: 2KEM) (145) so that consistent comparisons can be made between the
structures. The second β-strand is discontinuous, as also observed in the wild-type A3G-
CTD (144) and A3G-CTD-2K3A (143, 145) NMR structures. As previously observed, the cat-
alytic zinc is coordinated directly by H257, C288, and C291, and indirectly by the catalytic
residue E259 via a water molecule. Thus, in terms of the overall fold, this structure is
similar to the previously published structures but many key specific differences exist.
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Figure 2.1
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Figure 2.1 : Crystal structure of A3G191-384-2K3A with the α-helices highlighted in red
and β-sheets highlighted in yellow, labeled as in (145). The catalytic zinc ion is shown
in cyan and the intermolecular zinc ion is depicted in magenta in this and subsequent
figures.
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2.3.1 Crystal structure comparison
Comparison of A3G191-384-2K3A with the 3E1U crystal structure reveals numerous dif-
ferences (highlighted in green and blue in Figure 2.2(A)). Some of these differences are
in loop regions but other variations include large regions of secondary structure, notably
the β1-β2 region (M227-Q237), the β2′-α2 region (H248-G255), and the α2-β3 region (P267-
D274). In the A3G191-384-2K3A crystal structure, the second β-strand is discontinuous,
with residues L235-R239 forming a prominent “bulge”. This has been observed in both
mutant and wild-type A3G-CTD NMR structures (143–145).
Crystallography andNMRspectroscopy are complementary techniqueswithwell-established
methods for verifying the structural integrity of protein structures. PDB-REDO recently
organized someof the verificationof crystal structures in theProteinDataBank (158–160).
Unfortunately, the only other A3G-CTD crystal structure in the database was flagged as
having discrepancies in the PDB-REDO database (PDB ID: 3E1Uwith R-factor 25.2%, R-free
26.7%, Resolution 2.3Å). Many of the regions in the 3E1U structure (Holden et al., 2008)
that differ from the NMR structures, are regions where the 3E1U structure’s experimen-
tal data are the weakest (α-carbon B-factors shown in Figure 2.2(C)). The regions differing
between these structures include β1-β2, β2′-α2 and α2-β3.
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A3G-191-384-2K3A
PDB-ID 3IR2
Resolution 2.25Å
Temperature Cryogenic (−80°C)
Space group P212121
Cell dimensions
a 68.338Å
b 72.532Å
c 97.433Å
Molecules in AU 2
Completeness 96.9% (94.3%)
(Last shell 2.33 - 2.25)
Total reflections 153207
Unique reflections 22967
21796 (working)
I/σ 9.6
Ave. redundancy 6.7
Rmerge 7.5%
RMSD in
Bonds 0.0108Å
Angles 1.113°
Rfactor % 16.57
Rfree % 20.82
Water molecules per AU 379
Zinc atoms per AU 4
Ramachandran statistics (such residues per molecule)
“additionally allowed” regions 12
“generously allowed” regions 0
“disallowed” regions 1
Table 2.1
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Figure 2.2
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Figure 2.2 : (A) Major regions of structural differences between A3G191-384-2K3A and
3E1U highlighted in blue and green. Residues F268-D272, which were mis-traced in the
3E1U structure are highlighted in red. (B) NOE violations of more than 6Å (red lines con-
necting α-carbon atoms) calculated based on the A3G191-384-2K3A structure’s NMR data
(PDB ID: 2KEM) (145). (C) Differences in α-carbon B-factors. Color spectrum blue to red
depicts lowest to highest values. The overall α-carbon, B-factor range for the A3G191-384-
2K3A crystal structure is 13.0-52.18Å2, compared to 15.34–62.17Å2 for the 3E1U crystal
structure. (D) 2Fo-Fc electron density maps, contoured at sigma level 1.0, show the place-
ment of residues F268-D272 in three different structures: (i) the original and incorrect
3E1U, (ii) the rebuilt and corrected 3E1U, and (iii) the correct A3G191-384-2K3A crystal
structure.
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Evidence for ambiguity in the 3E1U structure is apparent in four ways: (1) 36 NOE re-
straints are violated in the 3E1U structure, by more than 6Å, with respect to NMR struc-
tural data; including in the very well-ordered α-helical and β-sheet regions that are well-
established by NMR (Figure 2.2(B) and Experimental Procedures). (2) In addition to be-
ing flagged in PDB-REDO, analyses of the structure and experimental structure-factors
of the 3E1U structure, downloaded from the Protein Data Bank (www.rcsb.org), revealed
seven residues that were in unfavorable Ramachandran space (3 in disallowed and 4 in
generously allowed regions). Most significantly, residues F268-D272 are completely mis-
traced in the electron density, burying K270 away from the surface (Figure 2.2(D)). These
residues, locatednear the endof α2-helix,maybe essential for the stability of theA3G-CTD
active site because mutating W269 or L271 abrogates deaminase activity (143). When we
re-fit this region in the 3E1U data, the final turn of α2-helix fit better within the electron
density (Figure 2.2(D)). Thus, the structure in this region converged towards the confor-
mation observed in the NMR structures not the one originally modeled in the 3E1U struc-
ture. The electron density in two other regions, β1-β2 and β2′-α2, remained ambiguous,
making refitting unattainable. (3) In contrast to these regions in the 3E1U structure, our
crystal structure of A3G-191-384-2K3A (R-factor 16.57%, R-free 20.82%, Resolution 2.25Å)
is well-ordered. Our structure of A3G191-384-2K3A has only 9 NOE restraint violations to
theNMRdata; the α2-helix is well ordered; and the structure has lower α-carbon B-factors
(Table 1) (Figure 2.2). (4) Mass spectrometry analysis validates that the β1-β2 structure is
conserved in full-length A3G. In contrast to the 3E1U structure, all NMR structures and
the A3G191-384-2K3A crystal structure show that residuesM227 andW232 are adjacent to
each other in the two neighboring beta-strands (β1-β2). This was verified by introducing
two cysteine mutations: M227C in β1 and W232C in β2, into both full-length A3G-2K3A
(Figure 2.11) and A3G (data not shown). Mass spectrometry determined that these two
residues, M227C andW232C, form a disulfide bond and no peptides containing freeM227C
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or W232C are detected in either construct. In the 3E1U structure, M227 andW232 are not
adjacent, rather R226 and L235 (part of the putative “continuous β2” strand) face each
other. Applying similar mass spectrometry analysis to full-length A3G, with mutations
R226C and L235C, did not result in a detectable peptide containing a disulfide bond (data
not shown).
Authors of the 3E1U structure write: “Therefore, an intact full-length β2 strand and
the five-stranded β-sheet core is probably the feature of wild-type APOBEC3G-CD2 and
all other APOBEC proteins.” (146). However, the A3G-191-384-2K3A crystal structure and
the additional experimental data described above do not support this statement. These
data suggest that the “bulge” observed between the β2-β2′ strands in NMR experiments
and the A3G-191-384-2K3A crystal structure, is not merely an experimental artifact but
an intrinsic feature of A3G-CTD structure.
2.3.2 Analysis of A3G191-384-2K3A crystal packing interfaces
The two molecules in the asymmetric unit in the crystal structure of A3G191-384-2K3A
pack in such a way as to produce four major interfaces, all of which are the result of
non- crystallographic symmetry, with surface areas of: 901Å2, 604Å2, 427Å2 and 246Å2,
respectively (figures below). Multiple sequence alignment of the A3G-CTD to ten other
homologs: A3G-NTD, A3A, A3B-CTD/NTD, A3C, A3DE-NTD/CTD, A3F-NTD/CTD and A3H
reveals that many of the residues contributing more than 30Å2 to these interfaces are
unique to A3G-CTD (Figure 2.3).
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Figure 2.3
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Figure 2.3 : Multiple sequence alignment of all human APOBEC3 protein sequences (Ref-
seq) by their respective NTDs and CTDs aligned to the A3G-CTD sequence. Residues con-
tributing more than 30Å2 to the buried surface area on an inter-molecular interface are
highlighted. Secondary structure elements of the A3G191-384-2K3A structure are shown
schematically above the sequence as brown rectangles for α-helices, yellow arrows for
β-strands, and black lines for loop regions. The coloring scheme does not represent se-
quence conservation but only highlights residues involved in forming the four major in-
terfaces.
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Figure 2.4
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Figure 2.4 : (A). Interface 1 (Figure 2.5) and (B). Interface 2 (Figure 2.7) residues colored by
sequence conservationbased on themultiple sequence alignment in (Figure 2.3). Coloring
scheme: Blue – Not conserved. Green – Partially conserved. Red – Fully conserved.
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The largest interaction interface (901Å2) displays excellent shape complementarity as
observed from the surface representation of interfacing molecules (Figure 2.5(A)). Exten-
sive surface contacts are observed, primarily between identical residues at the α1-loop-β1
frombothmolecules in the asymmetric unit. Twelve residues in eachmolecule contribute
at least 30Å2 to the interface, however, residuesW211, R213 and Q318 together contribute
over 450Å2 of the interfacial area (Table S1) (Figure 2.5(B)). None of these three residues
are conserved across the other APOBEC3’s (Figure 2.3 and Figure 2.4). Three direct hydro-
gen bonds, nine water-mediated hydrogen bonds and one ionic interaction, occur across
the entire interface (Table S2). All of these contacts verify the intimacy of this exten-
sive interface. As the residues forming this extensive interface are not conserved among
the other APOBEC3’s or the NTD of A3G (Figure 2.3 and Figure 2.4), this interface may be
unique to A3G-CTD.
2.3. RESULTS 54
Figure 2.5
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Figure 2.5 : Interface 1 between two A3G-CTD molecules in the asymmetric unit (A)
Surface representation and (B) details of the largest interaction interface. Molecule A
is shown in dark green, molecule B is shown in light green.
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To assess the functional significance of this interface, a variant of A3G was made with
the three amino acid substitutions W211A, R213A and R374E designed to profoundly dis-
rupt the observed packing. This variant shows near undetectable levels (background) of
DNA deaminase activity in vitro and abrogated anti-viral activity in the Vif-deficient HIV-
1 reporter virus assay (Figure 2.6(A), Figure 2.6(B)). In contrast, the active site A3G-E259Q
variant is catalytically dead and unable to inhibit Vif-deficient HIV-1, in agreement with
prior studies (161, 162) (Figure 2.6(B)). All of the variants studied have near normal cellu-
lar expression levels and incorporate into viral particles (Figure 2.6(C)). Thus the residues
that are integral to the first interface in the A3G191-384-2K3A crystal structure are essen-
tial to both A3G deaminase and anti-viral activity.
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Figure 2.6
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Figure 2.6 : DNA deaminase activity and HIV-1 restriction data. (A) A graph showing
the results of a DNA oligonucleotide-based deamination assay with the indicated A3G-
GFP constructs (MOCK: GFP only; WT: A3G-GFP; E259Q: A3G-E259Q-GFP; INT1: interface
1 A3G-GFP mutant (W211A, R213A, R374E); INT2: interface 2 A3G-GFP mutant (H248A,
H250A, C261A); INT3: interface 3 A3G-GFP mutant (H228A, V233R, L235R); INT4: inter-
face 4 A3G-GFP mutant (Y340A, S341A, K344A, D365A)). The y-axis reports the relative
fluorescence level (C-to-U activity), and the x-axis shows the amount of A3G-expressing
cell lysate used in each reaction. In most instances the SD of 3 replicas was smaller than
the symbol. (B) A histogram showing the relative infectivity of Vif-deficient HIV-GFP
produced in the presence the indicated A3G-GFP expression constructs or a GFP vector
control. This histogram presents the average of 2 independent experiments, each with
3 replicas. The error bars show the relative difference between the 2 data sets. (C). Im-
munoblots of cellular lysates and virus particles probed for A3G-GFP, CA andTubulin using
anti-GFP, anti-p24 and anti-tubulin antibodies, respectively.
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The second largest interface (604Å2) involves the β2′-loop-α2 residues 247–254 in each
of the two molecules of the asymmetric unit (Figure 2.7(A), Figure 2.7(B)). At this inter-
face, eight residues of eachmolecule bury extensive surface area, with the largest surface
area being buried by residues F252 and F268 (Table S1). This loop also coordinates an in-
termolecular zinc- binding site. H248 and H250 of one molecule in the asymmetric unit
and the secondmolecule’s C261 and D264 (through a water-mediated hydrogen bond) co-
ordinate an intermolecular zinc ion (Table S2). The combination of these four residues
occurring simultaneously is unique to A3G-CTD amongst the APOBEC3’s (Figure 2.3). An
additional four hydrogen/water mediated bonds are formed within this interface. This
zinc-coordinating interfacemay provide insights into how ametal mediated switch could
specifically modulate A3G oligomerization.
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Figure 2.7
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Figure 2.7 : Interface 2 between two A3G-CTD molecules in the asymmetric unit (A)
Surface representation and (B) detailed interactions. Same coloring scheme as in Fig-
ure 2.5. (C) Interface 2 overview with coloring based on data from HSQC spectra. Blue
residues: signal lost (I192, L193, S196, M197, D198, N208, R215, Y219, L220, Y222, V224,
R238, R239, G240, A243, N244, Q245, A246, L253, E254, G255, R256, H257, L260, C261, F262,
L263, V265, F268, W269, W285, S286, I314, G319, L325, F350, D352, S368, L371 and R374);
Yellow residues: chemical shift indicating fast exchange (T201, T203, F204, W211, T218,
E225, K234, D264, K270, L271, D316, T327, A333, I337, T339, S341, S372, G373, and R376).
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NMR experiments support Zn2+ mediated oligomerization at this interface. Through
titrationof Zn2+ into isotope labeledA3G191-384-2K3A, loss of signal intensities and chem-
ical shift perturbationswere observed at 1mMZn2+ (labeledblue, Figure 2.12). The residues
most affected are located in the β2′-loop-α2 and α2 regions. In fact, these residues in the
A3G191-384-2K3A crystal structure (blue, Figure 2.7(C)) map predominantly to the zinc-
coordinating second interface, described above, indicating that this interface may con-
tribute to zinc mediated oligomerization in solution.
To test the ability of zinc to modulate oligomerization a further series of NMR experi-
ments was performed. A reference HSQC spectrum was taken at 50μM of Zn2+ concentra-
tion (Figure 2.8(A)) then, Zn2+ concentration was increased to 1.25mM causing the disap-
pearance of amide proton NMR signals (Figure 2.8(B)). Next, 0.4 mM ethylenediaminete-
traacetic acid (EDTA) was added to chelate the free Zn2+. This caused the signals within
the NMR spectra to reappear (Figure 2.8(C)). The similarity of chemical shifts, signal in-
tensities and lineshapes of HSQC signals in (Figure 2.8(A) and (Figure 2.8(C))) combine to
suggest that zincmediates the equilibriumof A3G-CTD between oligomeric (Figure 2.8(C))
and monomeric states.
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Figure 2.8
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Figure 2.8 : Zn2+ dependent A3G191-384-2K3A aggregation is reversible. HSQC spectra
of A3G191-384-2K3A with (A) 50μM Zn2+, (B)1.25mM Zn2+, and (C)1.25mM Zn2+ / 0.4mM
EDTA. Protein concentration was 300μM for all spectra.
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A variant designed to disrupt this zinc binding site in the second interface, H248A,
H250A and C261A, shows normal expression levels and anti-viral activity (Figure 2.6(B),
Figure 2.6(C)). These observations demonstrate that zinc-mediated oligomerization may
not be essential for A3G’s HIV-1 restriction activity. This variant is partly defective for
DNA deaminase activity (Figure 2.6(A)). This alteration in DNA deaminase activity, may
be attributable to C261A alone (Chen et al., 2008), and was not significant enough to com-
promise A3G anti-viral activity. Thus the residues that are integral to the second interface
in the A3G191-384-2K3A crystal structure appear to impact A3G deaminase activity.
The third interface (427Å2) involves residues atN-terminal (β1-β2 strands) andC-terminal
ends of A3G191-384-2K3A (Figure 2.9(A), Figure 2.9(B)) (Table S1). Nine residues con-
tribute extensively to the interface with Q354 burying the largest surface area at this in-
terface followed by Q237, H228 and G355. In six of the eleven aligned APOBEC3 sequences
(Q or E354)/G355 are conserved (Figure 2.3) but not H228 or Q237. Four direct and three
water mediated hydrogen bonds are formed at this interface. Specifically, Q237 and R238
at the β2-β2′ “bulge” of one molecule (molecule A), form intermolecular hydrogen bonds
to N-terminal residues R194 (side chain disordered) and S196 with the other molecule
(molecule B). In addition, Q354 in the α5–α6 loop (molecule B) forms a hydrogen bond
with R226 in β1 (molecule A), this interaction is potentially conserved in APOBEC3A and
APOBEC3B-CTD. This interface would correspond closest to the β2-β2 interface observed
in APOBEC2, but is clearly not formed and would entail extensive rearrangement of the
α5 and α6 helices and their connecting loop. Of the four major interfaces, the packing of
the third interface is least complementary andmutations at this interface (H228A, V233R
and L235R) do not disrupt A3G’s DNA deaminase or antiviral activities (Figure 2.6).
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Figure 2.9
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Figure 2.9 : Interface 3 between two A3G-CTD molecules in the asymmetric unit (A) Sur-
face representation and (B) detailed interactions. Same coloring scheme as in Figure 2.5.
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The final of the four major interfaces buries a total of 246Å2 and involves substantial
burial of six residues from eachmolecule and the formation of two hydrogen bonds and a
salt bridge (Figure 2.10(A), Figure 2.2(B)) (Tables S1, S2). This interface is primarily made
up of the tops of the α5 and α6 helices. Interestingly, residues in α5 and α6 are also af-
fected by the addition of Zn2+. These residues showed small chemical shift changes in
HSQC spectra, suggesting that this region is involved in intermolecular interactions un-
der a fast exchange (labeled yellow, Figure 2.7(C), Figure 2.12). At this interface, residues
Y340 and D365 contribute most to the buried interface area. These two residues are well
conserved among the various APOBEC3’s (Figure 2.3) Y340 is conserved in all but one and
(D/E/Q)365 is conserved in eight of the eleven APOBEC3 sequences. Both of these residues
and the less conserved S341 are involved in hydrogen bonding; a salt-bridge is observed
between the moderately conserved K344 and D365. Although extensive sequence con-
servation is present, this interface is not as large as the others and a variant of A3G with
mutations Y340A, S341A, K344A and D365A has normal DNA deaminase and HIV-1 restric-
tion activities (Figure 2.6).
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Figure 2.10
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Figure 2.10 : Interface 4 between two A3G-CTDmolecules in the asymmetric unit (A) Sur-
face representation and (B) detailed interactions. Same coloring scheme as in Figure 2.5.
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2.4 Discussion
In this study, the crystal structure of the catalytically active C-terminal domainofAPOBEC3G
was determined to 2.25Å. This structure differs significantly from the previously pub-
lished crystal structure of this domain (PDB ID: 3E1U) (146). Here we have also demon-
strated that the 3E1U structure’s deposited experimental data do not unambiguously de-
scribe the structure deposited in the PDB. In contrast, our well-resolved crystal structure
of A3G191-384-2K3A validates the published mutant and wild-type NMR structures (143–
145), both in respect to the β2-β2′ “bulge” and a longer α2-helix with the residues F268-
D272 properly placed. Thus, this structure represents the first clearly resolved crystal
structure of the catalytic domain of APOBEC3G.
In addition mass spectrometry data support the observed β1-β2 conformation and
presence of a bulge between the β2-β2′ strands of the A3G catalytic domain. We veri-
fied the register of the β1-β2 secondary structure elements by probing the proximity of
key residues in this region through carefully engineered disulfide linkages. These results
thereby confirm the structural integrity of the β1-β2 conformation observed in all NMR
structures and the A3G191-384-2K3A crystal structure described here (143–145).
The unique interfaces observed between the asymmetric units of this crystal struc-
ture also lend insights into the potential role of oligomerization in APOBEC3G function.
Full-length APOBEC3G sequence displays pseudo-symmetry (Figure 2.3), yet none of the
largest interfaces observed in the crystal structure are conserved between the N- and C-
terminal halves of the protein sequence nor are do they position the termini in a manner
that could represent the full length enzyme. This is also consistent with the recentmodel
proposed for the full-length A3G holoenzyme (145).
Beyond the full-length A3G enzyme, oligomerization – often dimerization or tetramer-
ization – is a trend among the known deaminases. Escherichia coli cytidine deaminase
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and Staphylococcus aureus TadA form dimers; Bacillus subtilis cytidine deaminase, yeast
CDD1, and human cytidine deaminase form tetramers; and human ADAR1 and ADAR2 are
homodimers (60, 77, 163–168). Multiple studies have shown that A3G can exist in states
ranging frommonomer tomegadalton complexes (48, 116, 152, 169, 170). The importance
of A3G oligomerization to HIV-1 suppression is controversial; some studies conclude that
oligomerization is dispensable (123) while others claim that oligomerization is essential
(171). The present study adds new insights into the potential roles of these interfaces for
anti-viral and deaminase activities.
The surface(s) of A3G that forms these oligomers still remainunclear. SAXS, co-immuno-
precipitation and FRET studies have implicated the C-terminal half of A3G in oligomeriza-
tion (169, 170). Thisworkpotentially contrastswithmore recent co-immuno-precipitation
studies demonstrating that N-terminal residues are required for RNA-mediated dimeriza-
tion (171, 172). Possibly both sets of studies have some merit and two distinct surfaces of
A3G contribute to oligomerization.
Based on our analyses and data, we hypothesize that there are a variety of potential
surfaces for oligomerization. The interactions observed at the two most extensive inter-
faces, the α1-loop-β1 (Figure 2.5) and the β2′-loop-α2 (Figure 2.7) which coordinates a zinc
ion, represent unique A3G homo-oligomerization interfaces, while the tops of the α5 and
α6 helices (Figure 2.10) could modulate both homo- and hetero-oligomerization of the
different APOBEC3 family members.
A combination of solution NMR and the impact of variants designed to disrupt the in-
terfaces support the possibility that three of these interfaces may have functional signif-
icance. Mutations introduced to disrupt the first interface reduce both DNA deaminase
activity and anti-viral activity of A3G (Figure 2.6). However whether this is change in
activity is due to a change in oligomerization or direct disruption in nucleic acid bind-
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ing affinity remains to be determined. While mutations to disrupt the other interfaces
do not alter the anti-viral activity of A3G, these interfaces still may impact oligomeriza-
tion. The solution NMR data demonstrates a clear relationship between zinc-mediated
EDTA-reversible oligomerization and specific chemical shifts of residues most strongly
in the second interface that binds the intermolecular zinc but secondarily to the fourth
interface (Figure 2.8 and Figure 2.12). The functional significance of the zinc mediated
oligomerization remains to be elucidated.
Recent evidence indicates that binding of A3G to RNA may interfere with binding and
deamination of ssDNA in a concentration dependentmanner (173). High-Molecular-Mass
(HMM) A3G complexes, the dormant form of A3G, are comprised of RNA and other ri-
bonucleoproteins and the intermolecular interfaces described above may be required for
binding of A3G to RNA and/or packaging into HMM complexes. Furthermore, the dis-
ruption of HMM complexes into Low-Molecular-Mass (LMM) active form of A3G may be
achieved by small molecule ligands that weaken A3G–RNA binding by targeting the RNA
binding regions in A3G or the A3G interfaces required for the formation of HMM com-
plexes (174, 175).
The interfaces observed in this new A3G-CTD crystal structuremay therefore have im-
portant functional implications in the role of oligomerization for the activity of A3G and
will guide future studies.
2.5 Experimental Procedures
2.5.1 Protein expression and purification
BL21(DE3)-CodonPlus(RIL) (Stratagene, La Jolla, CA) bacterial cells, transformed with the
pGEX6P1-A3G191-384-2K3A vector (145, 150), were grown to an O.D.600 of 0.6 [TB media,
100 μg/ml Ampicillin and 34 μg/ml Chloramphenicol]. They were induced overnight [0.5
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mM IPTG, 18°C] to express GST-A3G191-384-2K3A. The cells were then harvested by cen-
trifugation [5000 rpm, 15min, 4°C] and re-suspended in lysis buffer [50mMNa2HPO4/NaH2PO4
(pH 7.4) and protease inhibitor (Roche, Basel, Switzerland)]. Resuspension was followed
by lysiswith a cell disruptor. The lysatewas centrifuged [43,000×g, 20min, 4°C] and the su-
pernatant incubated overnight with Glutathione-Sepharose (GE Healthcare, Piscataway,
NJ) beads. The beads were washed with lysis buffer and incubated with PreScission Pro-
tease (GE Healthcare, Piscataway, NJ) in cleavage buffer [50 mM Na2HPO4/NaH2PO4 (pH
7.4), 0.005% Tween20, and 1mMdithiothreitol]. A3G191-384-2K3A in the supernatant was
further purified by FPLC (Pharmacia/GE Healthcare, Uppsala, Sweden) using a Superdex-
75 size-exclusion column.
2.5.2 Protein crystallization
PurifiedA3G191-384-2K3Aproteinwas exchanged into crystallizationbuffer [50mMHEPES
pH 7.5, 1mM tris(2-carboxyethyl)phosphine, 50 μM zinc acetate, and 150mMNaCl] with a
PD-10 column (GE Healthcare, Piscataway, NJ). The protein was concentrated to 10mg/ml
using Amicon centrifugal filters (Millipore, Billerica, MA). Crystals were grown by the
hanging-drop/vapor-diffusion method on greased VDX plates (Hampton Research, Aliso
Viejo, CA) at 4°C with the reservoir solution [100 mM HEPES (pH 7.5), 10% Polyethylene
glycol 4000, and 100 mMmagnesium chloride].
2.5.3 Data collection and processing
Diffraction data for the A3G191-384-2K3A protein crystals were collected by synchrotron
radiation at ArgonneNational Laboratory (Advanced Photon Source, Chicago, IL) BioCARS
14-BMC under cryogenic conditions. Diffraction images were indexed and scaled using
the program HKL2000 (176); the structure was solved in P212121 space group at 2.25Å.
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2.5.4 Structure solution and refinement
The molecular replacement solution, calculated by PHASER (177) with the final transla-
tion function Z-score of 41.1, contained two molecules in the asymmetric unit. Phases
were subsequently improved by building solvent molecules using ARP/wARP (178). Re-
finement was carried out with REFMAC5 (179) in the CCP4 suite (180), with cycles of rigid-
body and restrained refinement; Non-Crystallographic Symmetry (NCS) restraints were
applied in the first two cycles and TLS parameters (181) were used in subsequent refine-
ment cycles. A free R-value with 5% of the data was used to limit the possibility of over-
refinement. Electron density was viewed by the program COOT (182) and was used for
model optimization.
2.5.5 Structure comparison and analysis
Graphical visualization and analysis was achieved using PyMOL (183). The interaction
interfaces formed between molecules in the A3G191-384-2K3A crystal were analyzed by
the Protein interfaces, surfaces and assemblies service PISA at European Bioinformat-
ics Institute (184). The NOE violations were calculated using accept.inp protocol of CNS
(185). The A3G-CTD crystal structure (PDB ID: 3E1U) was used as the input coordinate file
and the NOE files used to calculate the A3G191-384-2K3A NMR structure (PDB ID: 2KEM),
were set as NOE distance restraints. The algorithm PRANK, as implemented in the soft-
ware PRANKSTER, performed the multiple sequence alignments, with the +F option and
default values (186). All human APOBEC3 sequences were downloaded from the NCBI Ref-
seq database (APOBEC3A: NP_663745.1; APOBEC3B: NP_004891.3; APOBEC3C: NP_055323.2;
APOBEC3DE: NP_689639.2; APOBEC3F: NP_660341.2; APOBEC3G: NP_068594.1; APOBEC3H:
NP_861438.1) (187).
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2.5.6 DNA deaminase activity assays
The A3G-GFP and A3G-E259Q-GFP expression constructs have been described (161, 188).
All derivatives were constructed by combinatorial or sequential site-directed mutagen-
esis (Stratagene), with primer sequences available on request. The indicated A3G-GFP
or interface mutant expression constructs were transfected into HEK-293 cells using Fu-
gene (Roche). Cell lysates were prepared and DNA deaminase activities were measured as
described (189). The sequence of the single-strand DNA substrate was: 5′-(6-FAM)-AAA-
TTC-TAA-TAG-ATA-ATG-TGA-(TAMRA).
2.5.7 HIV-1 infectivity studies and immunoblots
These were performed as described (Harjes2009). HIV-GFP reporter viruses were pro-
duced by Fugene-mediated transfection (Roche) of 293T cells with a five plasmid cocktail
(190). The HIV-GFP proviral plasmid CS-CG, the Gag-Pol expression plasmid, the Rev ex-
pression plasmid, and the VSV-G envelope expression plasmid constituted 0.9 μg of the
cocktail, and the vector control or the A3G expression plasmid constituted the remaining
0.1 μg. Viruses containing supernatants were harvested 48 h post transfection by filtering
cell-free supernatants (0.22-μm PVDF; Millipore) and pelleting by centrifugation (20,000
g, 2 hrs). The resulting viral pelletwas resuspendeddirectly in SDS gel loading buffer, frac-
tionated by SDS-PAGE, transferred to a PVDF membrane (Millipore), and probed with an
anti-GFP antibody JL-8 (Invitrogen) to detect the A3G-GFP constructs. An anti-p24 mono-
clonal antibody (191) provided byM.Malim through theNational Institutes ofHealthAIDS
Research and Reference Reagent Program was used as loading control. Both monoclonal
antibodieswere detected using a horseradish-peroxidase-conjugated goat anti-mouse IgG
serum (Bio-Rad), followed by chemiluminescent imaging (Roche). After harvesting the
viral supernatants, A3G levels in virus-producing cells were monitored by extracting sol-
uble proteins with RIPA buffer (1 h, 4 °C, gentle rotation), removing particulates by cen-
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trifugation (10 min, 20,000 g), and immunoblotting, as described above. An anti-tubulin
monoclonal antibody (Covance) was used as cellular lysate loading control.
2.5.8 NMR Zn2+ titration experiments
15N-labeled A3G191-384-2K3A protein was expressed and purified (in 1mM DTT, 200mM
NaCl, 0.005% Tween 20 (Fisher scientific) and 50mM tris(hydroxymethyl)aminomethane
buffer, pH 8.0) as described in (145). ZnCl2 was titrated into 300 μM 15N-labeled A3G191-
384-2K3A at concentrations of 50μM, 200 μM, 400 μM, 600 μM, 800 μM, 1mM and 1.25mM.
A heteronuclear single quantum coherence (HSQC) spectrum was recorded at each Zn2+
concentration, which enabled specific amino acid chemical shift perturbations to be de-
tected. Bruker 700MHz equipped with a cryoprobe was used to collect all NMR spectra.
2.5.9 Mass spectrometry of cysteine mutants
Cysteine substitution variants were constructed using QuikChange protocol (Stratagene)
andverifiedbyDNAsequencing. A3G191-384-2K3A,A3G191-384-2K3A-M227C-W232C, A3G1-
384-M227C-W232C and A3G1-384-R226C-L235C were produced using the same procedure
as described in theprotein expression andpurification. Proteinswere isolated fromsodium
dodecyl sulfate (SDS) polyacrylamide gel after Coomassie Brilliant Blue (CBB) staining.
Isolated protein bands were digested using trypsin and subjected to mass spectrometry
(MS) at the Taplin Biological Mass Spectrometry Facility (Harvard Medical School). Both
high resolution full MS scans and high resolution MS/MS scans were performed using
LTQ-FT and LTQ-Orbitrap (Thermo Electron) to verify the peptide.
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2.6 Supplementary Data
2.6.1 Mass Spectrometry data
Figure 2.11
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Figure 2.11 : (A). An ion-selective chromatogram for the predicted mass of the disul-
fidepeptide inA3G1-384-2K3A-M227C-W232C. Apeptide containing the predictedM227C-
W232C disulfide bond was detected. The sequence of the peptide (C227HNDTCVK234) is
shown in the inset, similar data was seen for the wild-type construct (data not shown).
(B). A high resolution MS/MS fragmentation experiment to verify the peptide contain-
ing a disulfide bond. The only predicted ions that were detected are the ions outside the
disulfide bridge (green ovals). This is expected, as the presence of a disulfide bond hinders
peptide fragmentation. The peptide sequence is shown in the figure inset.
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2.6.2 HSQC data
Figure 2.12
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Figure 2.12 : Superimposition of the HSQC spectra of 15N-labeled A3G191-384-2K3A with
50μMZn2+ (black) and 1mMZn2+ (red). Residues numbers of signals that disappeared from
spectrum at 1mM Zn2+ concentration are labeled in blue. Residues numbers of signals
whose chemical shifts were moved at 1mM Zn2+ concentration are labeled in yellow.
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3.1 Abstract
The human APOBEC3G protein, a single-stranded DNA cytosine deaminase, functions as
part of the innate immune response to inhibit virus and transposon replication. APOBEC3G
is the prototype for the larger mammalian polynucleotide deaminase family, but no spe-
cific inhibitors exist to modulate this important enzyme. High-throughput screening
identified 34 compounds that inhibit APOBEC3G catalytic activity. 19/34 small molecules
contained catechol moieties, which are known to be sulfhydryl reactive following oxida-
tion to the orthoquinone state. Located proximal to the active site, C321 was identified
as the binding site for the inhibitors by a combination of structural analysis and muta-
tional screening. Covalent binding of a representative inhibitor to C321 was verified by
mass spectrometry. Bulkier substitutions C321-to-L, F, Y, or W were less active, mimick-
ing chemical inhibition. Thus, a structural model is presented in which the mechanism
of inhibition appears competitive, by sterically blocking substrate DNA cytosines from
entering the APOBEC3G active site.
3.2 Introduction
APOBEC3G (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G; A3G)
is a single-strand (ss)DNA cytosine to uracil (C-to-U) deaminase, which belongs to a larger
family of polynucleotideDNAandRNAediting enzymeswith a variety adaptive and innate
immune functions (120, 131, 192). A3G has become the prototype for understanding the
retrovirus and retrotransposon restriction activity of several family members, in large
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part because it potently inhibits Vif-deficient HIV-1 replication. Current working mod-
els posit that A3G packages into assembling viral particle through a RNA-Gag interaction,
travels with the particle until a new target cell becomes infected, and then interferes
with viral cDNA synthesis by deamination-independent mechanisms4 (likely by binding
viral genomic RNA and impeding reverse transcriptase progression) and deamination-
dependent mechanism (115, 121, 161). The hallmark of A3G restriction is minus strand
ssDNA C-to-U deamination events that are encoded as plus (genomic) strand G-to-A hy-
permutations. The predominant means by which HIV-1 can replicate in A3G-expressing
cells is by expressing its accessory protein Vif, a natural antagonist of A3G that recruits
an E3-ubiquitin ligation complex and promotes A3G degradation (76). The host-pathogen
conflict between cellular APOBEC3s and lentiviral Vif is not specific to HIV-1, as strong
evidence supports its existence in every othermammal that is infectedwith aHIV-related
virus (i.e., many types of non-human primates, carnivores such as cats, and agricultural
animals such as sheep and cattle (193–196)).
A3G is also the prototype for polynucleotide cytosine deaminase structure-function
studies, because it is the only catalytically active family member with high resolution
NMR and X-ray crystallography structures available to date (143–147,(and this study)).
Multiple structures and a strong similarity to other family members have produced a
range of scientifically useful models. However, the multiple interactions with A3G and
both RNA and DNA polynucleotides during the biological activity of this enzyme make it
imperative that these macromolecular associations become understood in as much detail
as possible. Moreover, major fundamental questions remain unanswered, such as why
are single strand DNA Cs and not RNA Cs deaminated and what is the oligomeric state of
the anti-viral form of A3G? Here, we explore a new approach toward understanding A3G
and its mechanism of DNA deamination by conducting high-throughput screens (HTS) to
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identify small molecules that inhibit its C-to-U deaminase activity. We have identified a
class of structurally similar compounds containing catechol moieties that react with an
A3G catalytic domain cysteine and most likely inhibit DNA deamination by a competitive
steric inhibition mechanism.
3.3 Results
3.3.1 Specific A3G inhibitors identified by HTS and sub-screening against
the related DNA deaminase APOBEC3A
To screen for smallmoleculeA3G inhibitors, wefirst optimized andminiaturized afluorescence-
based DNA deamination assay (189, 197, 198) (Figure 3.1). Full-length human A3G was
purified from HEK293T cells as a myc-His6 epitope-tagged protein (Figure 3.21). To ini-
tiate the assay, recombinant enzyme is incubated with a single-stranded DNA (ssDNA)
oligonucleotide containing a single target cytosine, a 6-FAM fluorophore at the 5’ end,
and TAMRA quenching molecule at the 3’ terminus. Deamination of the target cytosine
to uracil (C-to-U) is followed by uracil excision by E. coli uracil DNA glycosylase and sub-
sequent phosphodiester backbone cleavage by hydroxide, which releases the 6-FAM flu-
orophore from the TAMRA quench. Deaminase activity is quantified directly with a flu-
orescence plate reader. Using DMSO as a negative control and the non-specific inhibitor
aurintricarboxylic acid (ATA) found in preliminary screens as a positive control, the av-
erage Z-score in 384 well plates was 0.85 indicating that the assay is both robust and re-
producible (FluorDeaminaseAssayWorks and Figure 3.20).
The 1280 compound library of pharmacologically active compounds (LOPAC, Sigma)
was used to screen for chemical inhibitors of A3G. A total of 34 small molecules inhib-
ited ssDNA deaminase activity by at least 40% in two independent experiments (raw 384
well plate data in Figure 3.2). Dose response curves were generated to re-confirm in-
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hibitors and determine IC50 values, which mostly ranged from low- to mid-micromolar
levels (representative data in Figure 3.3; complete dose response set in Figure 3.23). Com-
pound structures are shown in Figure 3.4, and a summary of the 34 compounds relevant
to this study can be found in Figure 3.5.
By analogy to kinase inhibitor studies, which often use related enzymes to gauge com-
pound specificities (199–202), weperformed secondarydose response screensusingAPOBEC3A
(A3A), which is 65% identical (73% similar) at the amino acid level to the C-terminal cat-
alytic domain of A3G (Figure 3.21). Surprisingly, themajority (24/34) of compounds failed
to inhibit A3A, indicating a strong specificity for A3G (Figure 3.3 (B), (C) and Figure 3.5).
As an additional specificity test, all candidate active compounds were tested against the
second essential enzyme in our HTS reactions, uracil DNA glycosylase (UDG), by substitut-
ing uracil for the normal target cytosine in the ssDNA substrate (Figure 3.1, Figure 3.3 and
Figure 3.5). Only ATA (MN1) blocked UDG activity, concordant with prior studies showing
that this compound is a non-specific nucleic acid enzyme inhibitor (203–205) (Figure 3.3
(A) and Figure 3.5).
A total of 24 A3G-specific inhibitors were identified in LOPAC screens. One obvious
chemical trend emerged with 19/24 of these small molecules containing a common cat-
echol (ortho-dihydroxyphenyl) structure (Figure 3.5). Approximately 1% of all known
drugs possess a catechol pharmacophore, including at least 17 FDA-approved drugs (206).
Two prominent members of this family, apomorphine (MN2) and carbidopa (MN9), were
identified as A3G inhibitors. Based on this conserved structural feature and the estab-
lished clinical relevance of catechol pharmacophores, we focused additional studies on
this class of small molecule inhibitors with emphasis on methyl-3,4-dephostatin (MN30),
which re-confirmed through commercial sources and de novo synthesis (Figure 3.3 (C),
Figure 3.4, Figure 3.12, and Figure 3.19).
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Figure 3.1 : Schematic of the fluorescence-based single-strand DNA deamination assay.
APOBEC3G or APOBEC3A deaminates the cytosine in the substrate ssDNA oligo to a uracil,
which is excised by uracil DNA glycosylase (UDG). The remaining abasic site is cleaved
by basic hydrolysis so that the 5’ labeled 6-FAM fluorophore is released from 3’ labeled
TAMRA quencher and emits fluorescence at 520nm under excitation at 490 nm.
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Figure 3.2 : Representative High-Throughput-Screening (HTS) data. The screening with
1,280 LOPAC compounds was run in four 384 well plates. 40.5 nM of A3G, 6.7×10−4 Unit
of UDG, 333.3 nM of A3G substrate oligo (5’-6-FAM-AAA-CCC-AAA-GAG-AGA-ATG-TGA-
TAMRA-3’) and 10 μM of each compound were transferred into the reaction plates. The
first and last two columns in each LOPAC 384 well plate were filled with negative controls
(DMSO), positive controls (10 μM of ATA) or non-enzyme controls. Each X represents a
single data point and the red-shaded X’s signify confirmed inhibitors.
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Figure 3.3 : Dose response assay of three compounds MN1 (A), MN26 (B) and MN30 (C)
against A3G, A3A and UDG were run with dual-substrate oligo (5’-6-(FAM)-AAA-TAT-TCC-
CTA-ATA-GAT-AAT-GTG-A-(TAMRA)-3’) or UDG substrate oligo (5’-6-FAM-AAA-CCU-AAA-
GAG-AGA-ATG-TGA-TAMRA-3’). IC50 values are listed next to the corresponding curves.
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Figure 3.4 : Representative APOBEC3G inhibitors identified using the HTS assay.
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Figure 3.5
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Figure 3.5 : APOBEC3G inhibitor data.
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3.3.2 DNA binding assays suggest two mechanisms of A3G inhibition
To begin to functionally group the A3G inhibitors, we performed a series of ssDNA bind-
ing experiments using electrophoretic mobility shift assays (EMSAs). Prior studies have
shown that the A3G holoenzyme binds ssDNA with an affinities ranging from 50µM to
70µM and that this activity mostly emanates from the N-terminal pseudocatalytic do-
main, rather than the C-terminal catalytic domain (126, 127, 207). The ssDNA binding ac-
tivity of A3G is evident by several higher mass ssDNA-protein complexes visible in native
gels (207–209). Interestingly, a 80-fold molar excess of inhibitor (50 µM) enabled a rough
partition of all molecules into one of two general classes, those that block A3G from bind-
ing ssDNA and those that do not (Figure 3.6). Compounds representative of each class
were re-confirmed in dose response EMSAs (Figure 3.7). All but two of the repurchased
catechol analogues showed no inhibition of A3G’s ssDNA binding activity suggesting that
they function by binding within the C-terminal catalytic domain (e.g. MN30). The only
exceptions, MN10 and MN35, might also bind within the N-terminal domain. However,
these and the other molecules that may function by inhibiting ssDNA binding were not
considered further because we do not yet have the capacity to prepare sufficiently pure
quantities of A3G N-terminal nucleic acid binding domain or holoenzyme for structural
studies.
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Figure 3.6 : A3G-ssDNAcomplex formation is differentially affected by the indicated small
molecules (0.64 μM A3G, 0.08 μM ssDNA, 50 μM compound). As controls, DMSO did not
interfere with complex formation, and BSA did not cause complex formation.
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Figure 3.7 : Representative EMSAswith A3G, ssDNA, and 2, 5, and 10 μMofMN26 orMN30.
Most catechol containing compounds such asMN30 do not influence A3G-ssDNA complex
formation.
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3.3.3 Crystal structure indicates covalent binding of MN30 to APOBEC3G
We next leveraged the fact that the A3G C-terminal catalytic domain is well investigated
by structural studies using NMR spectroscopy and X-ray crystallography (143–147). Sev-
eral of the A3G inhibitors indentified above were used for co-crystallization experiments
with A3G-191-384-2K3A (L234K, C243A, F310K, C321A and C356A) (145, 147). A3G-191-384-
2K3A crystals were soaked with inhibitors and diffraction data obtained to 2.5Å. Positive
electron density was observed in the Fo-Fc map adjacent to C308 for MN30-soaked crys-
tals (Figure 3.8, Figure 3.9 and Figure 3.12). The refinement statistics and electron density
mapswere improved bymodeling theMN30 chemical structure onto the C308 region (Fig-
ure 3.9). Surprisingly, the 1.7Å estimated distance between the sulfhydryl group of C308
and the 5-position carbon of MN30 suggested a covalent linkage. Additional experiments
with MN30, MN30 analogues, and glutathione as a sulfhydryl substrate (one of the most
abundant in cells) demonstrated that MN30 autooxidizes under aerobic (O2) conditions
to the orthoquinone and then most likely forms a covalent bond with cysteine through
a Michael addition reaction (Figure 3.10 and S4). These results demonstrate that MN30
can indeed form a covalent linkage with the sulfhydryl group of cysteine, and specifically
with at least one cysteinewithin the A3G catalytic domain. However, wewere surprised to
find in parallel biochemical experiments that an A3G-C308Amutant still showedwildtype
susceptibility to MN30 inhibition (Fig. 4d), strongly suggesting that our crystal-soaking
experiments identified a secondary binding site.
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Figure 3.8 : Crystal structure of A3G-191-384-2K3A displaying the MN30 binding region.
The C308+MN30 adduct is displayed as a ball-and-stick representation with the C308 thiol
sulfur colored green. α-helices are colored red, β-sheets are colored yellow and the active
site Zn2+ and intermolecular Zn2+ atoms are represented as cyan and magenta spheres
respectively. Active site Zn2+ coordinating residues and the catalytic E259 are shown in a
ball-and-stick representation.
3.3.
RESULTS
106
Figure 3.9
3.3. RESULTS 107
Figure 3.9 : The 2Fo-Fc electron density map (blue mesh, contoured at sigma level 1.0),
at the C308+MN30 adduct region in the A3G-191-384-2K3A crystal structure. Atoms and
bonds are represented as sticks, with the C308 thiol sulfur colored green.
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Figure 3.10 : Chemical schematic showing the Michael’s addition reaction leading to for-
mation of MN30 adduct with a Cysteine residue.
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Figure 3.11 : A3G C308A mutation did not affect the deaminase activity. The full length
A3G-MycHis and A3G C308A-MycHis proteins showed similar activity and were both in-
hibited by MN30.
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Figure 3.12 : Crystallographic statistics for the A3G-191-384-2K3A (MN30 + Cys308) and
A3G191-380-2K2A (apo) crystal structures.
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3.3.4 Alanine mutagenesis revealed C321 as the A3G inhibitor-binding
site
TheA3G catalytic domainhas four surface cysteines C243, C308, C321 andC356, in addition
to partially exposed C288 and C291 that coordinate the active site zinc. The A3G catalytic
domain variant used above for our initial studies, A3G-191-384-2K3A, has three cysteine to
alanine substitutions, C243A, C321A and C356A. In the context of the full-length A3G pro-
tein, these three substitutions have no discernable effect on localization, deamination,
oligomerization, or Vif-deficient HIV-1 restriction activities (145, 147). This full-length
construct was purified and tested in parallel with wildtype enzyme against MN30. Inter-
estingly, this mutant enzyme was fully resistant to MN30 and all other catechol-based
inhibitors obtained from commercial sources (MN2, 5, 8, 10, 12, 13, 15, 16, 24, 28, 30, 32
and 35; MN3, 9, 11, 14, 17 and 31 were not tested) (Figure 3.13). Thus, one of the three
cysteines mutated in the 2K3A construct was most likely the biological target of this class
of A3G inhibitors.
To identify the inhibitor binding site, a series of three single cysteine to alanine mu-
tantswas constructed, purified to >80%homogeneity fromHEK293 cells asmyc-His tagged
proteins, and tested against representative inhibitors in the fluorescence-based ssDNA C-
to-U activity assay. Dose response data clearly revealed a single cysteine, C321, as the site
targeted byMN30 and related catechol-type inhibitors, as this single amino acid substitu-
tion was alone sufficient to render A3G fully resistant to chemical inhibition (e.g., MN30
data in Figure 3.14). Although the C321Amutant showed nearly the same level of catalytic
activity as wildtype A3G, variants with bulkier amino acid substitutions in place of C321
(to L, F, Y, and W) showed significantly diminished ssDNA deaminase activity, mimicking
the effects of MN30 and demonstrating that this amino acid position can impact catalytic
activity (Figure 3.24).
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Figure 3.13 : Full-length A3G-2K3A completely resists inhibition by all tested catechol
series inhibitors. The mean and SD of triplicate deaminase assays with 50 μM compound,
0.0675 μM A3G, 0.33 μM ssDNA, and excess UDG are shown relative to the DMSO only
controls.
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Figure 3.14 : A single amino acid substitution C321A defines the binding site in A3G for
catechol series inhibitors. Wildtype A3G and the indicated single alanine derivatives were
purified as described in the methods and Figure 3.21 and assayed in parallel with varying
concentrations of MN30. Data from triplicate assays were normalized to the DMSO only
controls, and the relative mean activities are presented with SD. Several other catechol
series molecules were also effective against A3G-C321A (data not shown).
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3.3.5 Additional proof that MN30 forms a covalent bond with A3G Cys321
To directly ask whether MN30 forms a covalent bond with A3G, we incubated it with full
length A3G, purified the protein by gel fractionation, performed in-gel digestion with
trypsin, and analyzed the resulting peptides by mass spectrometry. The C321 containing
tryptic peptide C*QEGLRTLAEAGAK showed a 167.11 Da addition demonstrating covalent
modification by MN30 (Figure 3.15). Both 2+ and 3+ charge states of the peptide were
detected and fragmented; the MS/MS spectra for both charge states resulted in highest-
scoring identification that corresponded to the C*QGELRTLAEAGAK peptide. The domi-
nant b-ion series observed in the MS/MS spectrum of the 3+ peptide suggests that MN30
is protonated in the gas phase, and the 167.11 Da mass reflects this. Similar LC-MS/MS
results were obtained with MN30 and the A3G191-380-2K2A protein (see below and data
not shown).
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Figure 3.15 : The MS/MS spectrum of the peptide C(167.11)QEGLRTLAEAGAK is depicted
with main b and y sequence ions annotated. The inset provides a table of predicted b and
y ion m/z ratios with detected ions indicated (bold, underlined). Masses in italics in the
table are not predicted to be present based on residues carrying charge in the peptide
and/or the mass range of the instrument.
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3.3.6 A structural model for competitive active site inhibition
To further understand themechanismofMN30 action, a newA3G C-terminal domain con-
struct was generated with C321 restored (A3G-191-380-2K2A). The “apo” crystal structure
of A3G-191-380-2K2Awas solved to a resolution of 1.38Å (Figure 3.16 and Figure 3.12). This
is the highest resolution crystal structure solved to date for the A3G catalytic domain en-
abling full resolution ofmost amino acid side chains. As described previously, the enzyme
is globular with a hydrophobic β-sheet core surrounded by six α-helices. Numerous at-
tempts were also made to co-crystallize or soak MN30 into existing A3G-191-380-2K2A
crystals, but these were unsuccessful. We suspect that upon binding C321, MN30 causes
conformational changes that may no longer permit our current constructs to crystallize
or it may be interfering with crystal packing.
Nevertheless, we took advantage of this new high-resolution structure to generate a
lowest energymodel of MN30 covalently bound to C321 (Figure 3.17 and Figure 3.18). This
model suggests amechanismof competitive inhibition through steric hindrance. The ring
structure of MN30 is predicted to be oriented towards the catalytic residues and cause
Y315 to flip such that it contacts W285, an essential residue lining the active site (143).
The net result is a model in which MN30 causes partial active site occupation by Y315,
which in turn is likely to prevent ssDNA cytosine from being bound and/or positioning
appropriately for catalysis.
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Figure 3.16 : Crystal structure of A3G-191-380-2K2A showing the location and orienta-
tion of C321, displayed in ball-and-stick and transparent CPK representations. α-helices
are colored red, β-sheets are colored yellow and the active site Zn2+ and intermolecular
Zn2+ atoms are represented as cyan andmagenta spheres respectively. Active site Zn2+ co-
ordinating residues and the catalytic E259 are shown in a ball-and-stick representation.
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Figure 3.17 : The 2Fo-Fc electron density map (blue mesh, contoured at sigma level 1.0),
around C321 and the active site region, in A3G-191-380-2K2A crystal structure. Atoms and
bonds are represented as sticks.
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Figure 3.18
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Figure 3.18 : TheMN30+C321 adductmodel, based on theA3G-191-380-2K2A crystal struc-
ture. The final model is displayed as cyan colored ribbons and ball-and-stick, with MN30
colored green, superimposed onto the A3G-191-380-2K2A crystal structure (white rib-
bons). Identical residues are displayed in both the model and the crystal structure and
labeled accordingly.
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3.4 Discussion
APOBEC3G is the prototypical enzyme for understanding themolecular biology, biochem-
istry, and the structural biology of DNA deaminase-mediated mechanisms of innate im-
munity to a variety of transposons and viruses including the retrovirus HIV-1. Here, we
report the results of HTS and follow-up studies that culminate in identifying the first
36 small molecule inhibitors of A3G deaminase activity. 22 of these compounds appear
to be A3G-specific inhibitors, because they do not block the activity of the related DNA
deaminase A3A or the unrelated E. coli uracil DNA glycosylase. Remarkably, 18/22 A3G-
specific compounds contain a catechol (ortho-dihydroxyphenyl) structure, which is a
chemical feature of approximately 1% of all known drugs (206). A combination of genetic
and physical techniques, with emphasis on methyl-3,4-dephostatin (MN30), combined to
demonstrate that this class of small molecules blocks A3G activity by covalently linking to
the C321 sulfhydryl group and thereby sterically interfering with active site amino acid
residues (particularly the essential residues Y315 and W285 (143)).
The fact thatMN30 andmost likely all of the other catechol-type compounds described
here can react with two cysteines in A3G (C308 and C321) and one in glutathione suggests
that these small molecules are not completely specific. However, the fact that they do not
inhibit the related deaminase A3A (5 cysteines) or the second enzyme in our deaminase
assays uracil DNA glycosylase (1 cysteine) suggests that these compounds may at least be
semi-specific. It is likely that the cysteine reactivity information can be used together
with the new 1.38Å A3G catalytic domain crystal structure also described here to per-
form virtual docking and molecular dynamic simulations of related catechol containing
molecules to identify a subset with improved specificity for the A3G active site.
Interestingly, methyl-3,4-dephostatin (MN30) is a rationally-designed analogue of de-
phostatin (MN10). Dephostatin is a natural product isolated from Streptomyces that in-
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terferes with protein tyrosine phosphatase activity (210–212), but it proved too unstable
for most biological applications (213). In an effort to identify dephostatin analogues with
enhanced potency, methyl-3,4-dephostatin (MN30) was synthesized and found to possess
similar protein phosphatase inhibitory activity as compared to its parent natural product
MN10 (214). The molecular mechanisms of MN30-binding to protein phosphatases have
been well studied and this compound has demonstrated efficacy in a murine model of di-
abetes following oral dosing (215). Our future studies will be directed toward expanding
DNA deaminase inhibitor HTS, directedmedicinal chemistry, and usingMN30 and deriva-
tive compounds as molecular probes to further dissect the innate immune and antiviral
functions of A3G.
3.5 Experimental Procedures
Proteins:
A3G-myc-His andA3A-myc-Hiswere purified from stably transfected or transiently trans-
fected HEK293T cells using the C-terminal hexahistine tags, as described (197, 198).
C-to-U assay:
The fluorescence-based assay has been reported and refined (189, 197, 198). Recombi-
nant human A3A-myc-His and A3G-myc-His proteins were diluted with 50 mM Tris.Cl,
pH 7.4, 150 mM NaCl, 10% Glycerol and 0.5% Triton X-100 to intent concentration. 20 µl
of the solution were incubated with 10 pmol substrate DNA oligo (Biosearch Technolo-
gies, Inc.) and 0.02 unit of UDG (NEB) diluted in 20 µl of 50 mM Tris.Cl, pH7.4, 10 mM
EDTA for 2 h at 37 °C in Nunc 384-well black plates. 3 µl of 4N NaOH was added, followed
by mixing and incubating at 37°C for another 30 min. 3 µl 4 N HCl and 27 µl 2M Tris.Cl
(pH7.9) was then added for neutralization and the relative deaminase activity was quanti-
fied by reading fluorescencewith excitation at 490 nm and emission at 520 nmon Synergy
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Mx Monochromator-Based Multi-Mode (BioTek Instruments, Inc.) or LJL Analyst AD (LJL
BioSystems, Inc.) microplate readers.
HTS including specifics on instrumentation:
(i) Compound transfer: 40 nl of library compound (10 mM in DMSO), aurintricarboxylic
acid (ATA, 10 mM in DMSO; positive control), or DMSO (negative control) were tranfsered
into Nunc 384 well plate (#262260) using an ECHO 550 Liquid Handler (Labcyte Inc.).
(ii) Protein addition: Add 20 μl of recombinant A3A-Myc-His A3G-Myc-His assay solution
to each well of the 384 plate using a Perkin Elmer Flexdrop Reagent Dispenser; mix by
shaking on a DPC micromix shaker for 1min (form 20, amplitude 7), and incubate for 15
min at 37°C.
(iii) Substrate addition: Add 20 μl single-strand DNA oligo solutionwith E.coli UDG to each
well of 384 well plate using a Perkin Elmer Flexdrop Reagent Dispenser; mix by shaking
on a DPC micromix shaker for 1 min (form 20, amplitude 7), and incubate for 2 hours at
37°C.
(iv) Product cleavage: Add 3 μl of cleavage solution (4N NaOH) using a Perkin Elmer Flex-
drop Reagent Dispenser, mix by shaking on a DPC micromix shaker for 1 min (form 20,
amplitude 7), and incubate for 30 minutes at 37°C.
(v) Reaction neutralization: Add 30 μl of neutralization solution (1.8M Tris-Cl (pH 7.9),
0.4N HCl) using a Perkin Elmer Flexdrop Reagent Dispenser; mix by shaking on a DPC mi-
cromix shaker for 1 min (form 20, amplitude 7) at room temperature.
(vi) Read-out: Quantify fluorescence with excitation at 490 nm and emission at 520 nm
using a LJL Analyst AD (LJL BioSystems, Inc.).
Electrophoretic mobility shift assays:
A3G-mycHis protein was incubated together with fluorescein labeled single strand oligo
at 37°C for 30 min. The reaction products were subjected to electrophoresis in TBE poly-
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acrylamide gel of indicated concentration. The oligo shift were imaged at 463 nm.
Crystallization and High-resolution crystal structures:
A3G-191-384-2K3A and A3G-191-380-2K2Awere expressedwith GST-tags and purified and
crystallized as described earlier (147). MN30 dissolved in DMSO at 1 mM stock concentra-
tion was added to crystallization drops with A3G-191-384-2K3A crystals and incubated
for 12 hours followed by flash freezing in liquid nitrogen and data collection under cryo-
genic conditions. Data for A3G-191-384-2K3A crystals soaked with MN30 was collected
on a R-AXIS IV detector system (Rigaku Inc.) at the Univ. Mass. Med. Sch. and for
the A3G-191-380-2K2A “apo” crystals at GM/CA-CAT beamline at the Advanced Photon
Source (APS, ANL, Chicago, IL). Data processing and reduction for MN30 soaked A3G-191-
384-2K3A crystals was donewithHKL2000 (176, 216) and that for A3G-191-380-2K2A “apo”
crystals with XDS (217) as provided via the Xia2 package (218). In both cases, further re-
finement was carried out using Refmac5 (179, 219) as provided in the CCP4 software suite
(180) and the model building done using Coot (182). PyMOL (Schrodinger LLC) was used
for viewing final structures and generating images.
Modeling the C321+MN30 adduct:
The MN30+Cys321 adduct was modeled into the A3G-191-380-2K2A crystal structure us-
ing the Prime “Covalent Docking” module (220–222) as provided in the software Maestro
(223), following standard protein and ligand preparation modules and protocols as pro-
vided by the vendor (Schrodinger LLC). The ligand interaction diagramwas also generated
using Maestro.
Mass Spectrometry:
Purified A3G-mycHis reacted with MN30 was separated by SDS-PAGE and stained with
Coomassie. A3G bands were excised from the gel and digested with trypsin (224, 225).
Extracted peptides were resuspended in 20 µl of 0.1% formic acid and analyzed by LC-
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MS/MS on an LTQ Orbitrap XL mass spectrometer (Thermo Scientific) equipped with a
nanoACQUITY autosampler and chromatography system (Waters). 5 µl of each sample
was injected onto a nanoACQUITY Symmetry C18 trap (5 um particle size, 180 um x 20
mm) in buffer A (0.1% formic acid) at a flow rate of 4 µl/min and then separated over a
nanoACQUITYBEHC18 analytical column (1.7 µmparticle size, 100 µmx100mm)over two
hrs with a gradient from 2% to 25% buffer B (99.9% ACN, 0.1% formic acid) at a flow rate
of 0.4 µl/min. The mass spectrometer continuously collected data in a data-dependent
manner, collecting a survey scan in the Orbitrap mass analyzer at 40,000 resolution with
an automatic gain control (AGC) target of 1 x 106 followed by collision-induced dissoci-
ated (CID) MS/MS scans of the 10 most abundant ions in the survey scan in the ion trap
with an AGC target of 5,000, a signal threshold of 1,000, a 2.0 Da isolation width, and 30
ms activation time at 35% normalized collision energy. Charge state screening was em-
ployed to reject unassigned or 1+ charge states. Dynamic exclusion was enabled to ignore
masses for 30 s that had been previously selected for fragmentation. The collected mass
spectra were searched against the SwissProt database (downloaded 1/11/11) using the
Protein Prospector software suite (226). To identify potentially MN30-modified peptides,
a secondary search was performed against on the sequence for A3G allowing mass modi-
fications between 160 to 170 Da to any cysteine.
APOBEC3A Homology Model:
TheA3G-191-380-2K2A crystal structurewasused as the template formodeling theAPOBEC3A
sequence (RefSeqGI:300869638) using the comparativehomologymodelingmodule PRIME
(220–222), as available in the softwareMaestro (223). The resultingmodelwas subjected to
Polak-Ribière conjugate gradients (PRCG) energyminimization, also available inMaestro,
until the gradient converged. The final model satisfied Ramachandran plot constraints
and no steric clashes were present.
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3.6 Supplementary Data
Figure 3.19
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Figure 3.19 : Synthesis of MN30 and des-nitroso 5. Reagents and conditions: i. TBSCl, im-
idazole, DMAP, DMF, 89%; ii. H2 (1 atm), Pd/C, EtOH, 91%; iii. (CF3CO)2O, pyridine, CH2Cl2,
96%; iv. NaH, DMF; MeI 76%; v. K2CO3, MeOH, H2O, 66%; vi. TBAF, THF, AcOH 63%; vii.
NaNO2, HCl, THF, 76%; viii. NaH-HF buffer, 72%.
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Figure 3.20
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Figure 3.20 : HTS data in tabular format.
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Figure 3.21
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Figure 3.21 : (A),(B) Image of Coomassie Blue-stained A3G- and A3A-mycHis proteins
purified from HEK-293T cells. BSA standard is shown for comparison. (C),(D) Activities
of the indicated proteins in the fluorescence-based DNA deaminase assay. The A3G as-
say used 5’-6-FAM-AAA-CCC-AAA-GAG-AGA-ATG-TGA-(TAMRA)-3’ and the A3A assay 5’-
6-FAM-AAA-TTC-AAA-GAG-AGA-ATG-TGA-(TAMRA)-3’.
3.6.
SUPPLEM
ENTARY
DATA
140
Figure 3.22
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Figure 3.22 : (A) The relative fluorescence readings for an entire 384 well plate with 16
identical samples in each column replicated six times through the plate. Columns 1, 5,
9, 13, 17, 21 report uninhibited reactions: 0.0405 μM A3G-mycHis, 0.0333 μM ssDNA sub-
strate (5’-6-FAM-AAA-CCC-AAA-GAG-AGA-ATG-TGA-TAMRA-3’), and excess 6.7×10−4 units
UDG. Columns 2, 6, 10, 14, 18, 22 report ATA-inhibited reactions, otherwise identical to the
positive reactions. Columns 3, 7, 11, 15, 19, 23 report reactions with no A3G, but otherwise
identical to positive reactions. Columns 4, 8, 12, 16, 10, 24 report reactions with no ssDNA
substrate, but otherwise identical to positive reactions. The raw fluorescence reading of
a 384 well plate, 16 samples in each column. (B) The mean value ±S.D. of each column of
raw data shown in (A). The average Z-score in 384 well plates was 0.85.
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Figure 3.23
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Figure 3.23 : Dose response data for 34 compounds. All 34 compounds were tested with
0.0405 μMA3G-mycHis, 0.0038 μMA3A-mycHis, or 6.7×10−4 units/μl UDG in dose response
assays using 0.033 μM ssDNA substrate (dual substrate oligo 5’-6-(FAM)-AAA-TAT-TCC-
CTA-ATA-GAT-AAT-GTG-A-(TAMRA)-3’ for A3G and A3A; U oligo 5’-6-FAM-AAA-CCU-AAA-
GAG-AGA-ATG-TGA-(TAMRA)-3’ for UDG). All dose responses were done in triplicate, and
the mean ±S.D. is shown for each concentration. 8-point (not shown) and 12-point dose
response curves were generated for all repurchased compounds; only 8-point dose re-
sponse curves with A3G and A3A (not UDG) were generated with non-repurchased small
molecules. Relevant IC50 values are indicated here and all IC50 values are listed in Table 1.
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Figure 3.24 : Wildtype A3G-mycHis or the indicated C321 mutant derivatives were ex-
pressed in HEK293T cells. 48 hrs post-transfection, soluble cell extracts were prepared,
quantified, and assayed in triplicate for DNA C-to-U activity using a fluorescently labeled
dual A3A/A3G ssDNA substrate oligo as described (189, 197, 198). Anti-c-myc immunoblot-
ting showed that each proteinwas expressed at similar levels, and anti-β-tubulinwas used
as a loading control.
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4.1 Introduction
The APOBEC3 subfamily of proteins, a subset of the greater APOBEC family of cytidine
deaminases, are essential for controlling endogenous retrotransposons (e.g. Long Inter-
spersed Nuclear Element 1: LINE-1) (227, 228) and for anti-retroviral immune response
(e.g. HIV-1) (57, 229). This subfamily of APOBEC proteins, found in all primates and most
mammals, has been under positive evolutionary selection over the past 33 million years
(92). Human chromosome 22 (locus q13.1) has been identified to carry the entire APOBEC3
gene family, consisting of seven members, abbreviated as A3A, A3B, A3C, A3D/E, A3F, A3G
and A3H (48, 230). The intracellular localization and functions of APOBEC3 family mem-
bers are distinct, for example, A3A has been observed cell-widewith a nuclear preference,
A3C is cell-wide, A3F and A3G are predominantly cytoplasmic and A3H is again cell-wide
but with a propensity for nucleoli (142, 227). The protein sequences of APOBEC3 pro-
teins reveal a shared underlying architecture characterized by zinc-binding signature se-
quences or Z-domains (95).
The three Z-domain signature sequences are:
Z1: [x6−11HxEx5xxx17SWS/TPCx2−4Cx6Fx8Lx5RIYx8−11Lx2Lx8xMx3−4]
Z2: [x3−7HxEx5WFx16−20SWS/TPCx2Cx6Fx8Lx5RLYx8−11Lx2Lx8−12xMx3−4]
Z3: [x3−4HxEx5xxx14−17TWSPCx2Cx6Fx8Lx5RLYx10Lx2Lx8VMx3−4]
Four of the seven human APOBEC3 proteins contain two Z-domains, A3B (Z2/Z1), A3D/E
(Z2/Z2), A3F (Z2/Z2) and A3G (Z2/Z1), that are believed to have arisen as a result of gene
duplication events (94). The remaining three carry a single Z-domain: A3A (Z1), A3C (Z2)
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and A3H (Z3) (Figure 1.2.1). The Z-domain signatures are merely sequence patterns and
do not signify the presence or absence of catalytic ability. For instance A3A, A3C and A3H
each contain a single catalytically active Z-domain, Z1, Z2 and Z3 respectively. A3F and
A3G, both contain two Z-domains with only the C-terminal domain being catalytically
active and the catalytically-inactive domain being more relevant to substrate binding.
A3B also contains two domains and both are catalytically active.
The availability of high-resolution structures of various proteins has enabledmodeling
of related proteins by homology modeling, an approach that has been validated and em-
ployed successfully over the last three decades (231, 232). Recent literature describes ho-
mologymodeling attempts based on APOBEC2 (157) and A3G-CTD structures, for example
the homologymodels of A3G-NTD (70, 144, 145, 233), APOBEC3A (234) and APOBEC3F-CTD
(70, 235). Homology models of multiple related proteins are useful for comparing shared
structural features or to highlight differences and distinguishing characteristics amongst
family members. Furthermore, these models may be used for generating new hypothe-
ses thatmay be satisfied by prior experimental data or be verified by further experiments
designed to test one or more aspects of such hypotheses.
4.2 Results
4.2.1 Sequence Analysis
The high-resolution crystal structures of humanAPOBEC3G catalytic/C-terminal domain,
discussed in the previous chapters (147), have the potential to serve as reliable templates
formodelinghomologousAPOBEC3 familymembers, as evident from themultiple-sequence
alignment of six APOBEC3 domains to the crystallized (mutated) A3G-CTD and wild-type
A3G-CTD sequences (Figure 4.1). The sequences were selected to represent all three Z-
domains, including a catalytically inactive Z2 domain (A3G-NTD). The sequence align-
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ment highlights the features shared across the listed APOBEC3 family members, such as,
the active-site catalytic glutamate (Glu259 inA3G-CTD) and the zinc coordinating residues
(His257, Cys288 and Cys291 in A3G-CTD). In addition to the corresponding Z-domain sig-
nature residues, highlighted in Figure 4.1 by colored dots and corresponding to Figure 1.3,
several other residues are also absolutely conserved across the sequences.
4.2.
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Figure 4.1
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Figure 4.1 : Sequence alignment of the homology modeled human APOBEC3 sequences
to the template A3G-CTD crystal structure sequence. Identical residues are highlighted
in green, zinc coordinating residues are indicated by blue rectangles and the catalytic
glutamate residue is indicated by the red rectangle. The colored circles represent residues
listed in each Z-domain signature, with the colors matching Figure 1.3 as per references
(94, 95).
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4.2.2 Phylogenetic Analysis
Not surprisingly, phylogenetic analysis based on the multiple-sequence alignment (Fig-
ure 4.2), reveals a partitioning or clustering amongst the sequences that corresponds to
the three Z-domain signatures, likely arising as a consequence of their evolutionary his-
tory (94). Based on branch lengths, the Z1 domain proteins, A3A, A3B-CTD and A3G-CTD
appearmore closely related to each other and to the Z3 domain protein A3H, whereas, the
Z2 domain proteins A3C, A3F-CTD and A3G-NTD form a distinct group, as has also been
observed in previous analysis (94). This phylogenetic analysis suggests a framework for
expected divergence in homology models built based on the A3G-CTD crystal structure
template (sequence: A3G-XTAL), for example, the A3G-NTD model may diverge far more
from the template than the A3A model.
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Figure 4.2
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Figure 4.2 : Phylogenetic tree based on sequence alignment fromFigure 4.1. The branches
are colored as per the Z-domain coloring in Figure 1.3 (Z1: green, Z2: orange, Z3: blue).
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4.2.3 Features of APOBEC3 homology models
Common structural core
All APOBEC3 homology models share secondary structural features with the template
structure but differ primarily in the length and orientation of loop regions, with A3G-NTD
model diverging most from the template. The best-fit average Cα RMSD values for the six
models with respect to the template A3G-CTD crystal structure are 0.921Å – A3A, 1.028Å
– A3B-CTD, 2.645Å – A3H, 1.578Å – A3C, 1.741Å – A3F-CTD and 5.42Å – A3G-NTD. Ana-
lyzing these homology models using computational statistical methods (core.findmethod
in ref. 236), reveals a common minimal “core” of structural similarity across all mod-
els (Figure 4.3). Structural alignment of all APOBEC3 homology models and the template
structure shows very good agreement around the “core” region (Figure 4.4). As may be
expected, a majority of residues making the “core” are completely conserved across the
template and target APOBEC3 protein sequences (Figure 4.1).
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Figure 4.3 : A histogram of the “core” ellipsoid volumes against the number of residues
considered as a part of the core in all APOBEC3 homology models. Based on data gen-
erated using Bio3D (236). The Y-axis represents the total ellipsoid volume as defined by
(237) and the X-axis represents the number of residues contributing to the ellipsoid vol-
ume. A “core” comprises a set of residues, across multiple structures, that have minimal
structural deviation with respect to each other and thus a minimal total volume as calcu-
lated after three-dimensional superimposition.
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(a) All APOBEC3 homology models
(b) Core region in A3G-CTD
Figure 4.4
4.2. RESULTS 159
Figure 4.4 : The “core” region is highlighted in all APOBEC3 homology models (orange
mesh) and the template APOBEC3G-CTD crystal structure (orange cartoon). The atoms
in the “core” region correspond to atoms from the following A3G-CTD residue numbers:
205, 206, 219–222, 257, 258, 281–284, 309–314, 336–338, 340–351, 363, 364 and 366–375.
Active-site Zn2+: Cyan spheres. Secondary-zinc-binding-site Zn2+: Magenta spheres.
4.2. RESULTS 160
Surface electrostatic potential
The most striking difference across the homology models lies in the surface charge dis-
tribution as suggested by electrostatic potential calculations (Figure 4.5). The orientation
depicted in Figure 4.5 and Figure 4.6 is a direct “top” view looking at the enzyme active-
site region and shows great heterogeneity in electrostatic potential across the six models
and the template. APOBEC3H, a single-domain Z3 domain protein, shows very large pos-
itively charged regions around the active site compared to all other models (Figure 4.6f).
In contrast, APOBEC3C, another single-domain protein, but with a Z2 signature, is not as
strongly charged around the active site, with the majority of positive charge localized
around the C-terminal helical region (Figure 4.6c). Similarly, APOBEC3A (Figure 4.6a),
with a single Z1 domain, appears more positively charged near the active site region ad-
joining the N-terminus as compared to the other two Z1 domains, APOBEC3B-CTD (Fig-
ure 4.6b) and theA3G-CTD template (Figure 4.5a). The same is true for theAPOBEC3G-NTD
(Figure 4.6e) that appears more positively charged compared to A3G-CTD.
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(a) A3G-CTD overview
(b) Active site region
Figure 4.5
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Figure 4.5 : Electrostatic potential surface representation of the template APOBEC3G-CTD
crystal structure. Red represents negative and blue represents positive potential with the
numerical range between -0.125 — +0.125 kcal/M
.
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(a) APOBEC3A
(b) APOBEC3B-CTD
(c) APOBEC3C
Figure 4.6
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(d) APOBEC3F-CTD
(e) APOBEC3G-NTD
(f) APOBEC3H
Figure 4.6
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Figure 4.6 : The human APOBEC3 family homology models – Top view – looking down
into the active site region.
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4.3 Discussion
The APOBEC3 sequences selected for this study represent all three Z-domain signatures
and are catalytically active except for one Z2 domain member, APOBEC3G-NTD. Multiple
sequence alignment displays the consensus in regions defining each of the Z-domain sig-
natures, whereas, the differences suggest regions that may play important roles in sub-
strate specificity and binding avidity across these proteins. The phylogenetic analysis
identifies a spontaneous clustering of these sequences based on their Z-domain signa-
tures, with A3H (Z3) on a separate branch from the A3G-CTD, A3A and A3B-CTD (Z1) and
the A3G-NTD, A3F-CTD and A3C (Z2) branches. The phylogenetic distance between the
modeled proteins and the template sequence correlatedwith the RMSdeviations between
the template structure and final homology models. The fact that A3G-CTD and A3G-NTD
are on distinct branches suggests “unequal crossing-over” gene-duplication events as dis-
cussed and illustrated in (94).
Structural dissimilarity across the homology models was contrasted by a structurally
similar “core” region that loosely corresponds to the conserved residues in the multi-
ple sequence alignment. This “core” may signify residues retained during evolution to
maintain structural integrity and provide the fundamental scaffold required for proper
folding, structural stability, oligomerization, substrate binding and enzymatic function.
The electrostatic potential surfaces highlight the structural variation across theAPOBEC3
homology models that may contribute to substrate binding affinities, oligomerization
propensity and interactions with human and viral (HIV-1 vif) proteins or nucleic acids.
For instance, APOBEC3Hmaybindmore readily to the negatively chargedDNA/RNAphos-
phodiester backbone due to the highly positive electrostatic potential on its surface, sug-
gesting a possible explanation for binding and catalysis by a single-domain APOBEC3 pro-
tein. Based on similar observations, the argument may be extended to other two single-
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domainAPOBEC3 proteins, A3A andA3C, by proposing that extent of positive electrostatic
potential on the protein surface determines binding affinity to substrates and other pro-
teins.
HIV-1 vif is an important determinant of viral infectivity as it binds A3G and targets
it for proteasomal degradation. Residues 126–132 in A3G-NTD and 283–300 and Glu324 in
A3F-CTD have been implicated as specificity determinants in binding to vif (Figure 4.7)
(131, 233, 235). Comparing these regions in the A3G-NTD and A3F-CTD to A3G-CTD, the
role of electrostatic potential in directing this interaction appears to be important. Fur-
thermore, HIV-1 vif, the nemesis of human A3G, is known to contain large swaths of posi-
tively charged surface residues that are required for binding negatively charged residues
on A3G-NTD surface and directing it towards proteasomal degradation (131, 238). Com-
paring theA3G-NTDmodel’s surface electrostatic potential to thehighly positively charged
A3H model (Figure 4.8) immediately suggests that unfavorable charge interactions, even
electrostatic repulsion, may be a major reason for A3H to escape binding and neutraliza-
tion by HIV-1 vif (239).
The homology models described and analyzed in this study may serve as a foundation
for building experimentally testable hypotheses to further our understanding of the hu-
man APOBEC3 family of proteins in terms of structural features, binding interactions and
biological activity.
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(a) A3F-CTD vs A3G-NTD
(b) A3F-CTD vs A3G-NTD Electrostatic Surface
Figure 4.7
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(c) A3F-CTD vs A3G-NTD
(d) A3F-CTD vs A3G-NTD Electrostatic Surface
Figure 4.7
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Figure 4.7 : HIV-1 vif binding residues highlighted in A3F-CTD (magenta, green (Glu324))
and A3G-NTD (blue) homology models. Based on data from 131, 233, 235.
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Figure 4.8
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Figure 4.8 : A side-by-side comparison of the of the A3H and A3G-NTDmodels displaying
the contrast in surface electrostatic potential that may be critical to binding and degra-
dation by HIV-1 vif (239).
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4.4 Methods
4.4.1 Sequence and Phylogenetic analysis
Sequences for the human APOBEC3 proteins used for this study were downloaded from
NCBI RefSeq database (187). Dual-domain sequences were iteratively pairwise-aligned
after dividing the sequences at putative domain boundaries using MUSCLE (240, 241), un-
til an acceptable alignment between the two domains was obtained. The phylogenetic
tree was constructed from the multiple sequence alignment based on tools available at
the website http://www.phylogeny.fr (242–246) and visualized using the UGENE software
(Unipro UGENE: an open-source bioinformatics toolkit; http://ugene.unipro.ru).
4.4.2 Homology Modeling and Electrostatic potential surfaces
All homology models were generated using the high resolution APOBEC3G-CTD crystal
structure, based on the A3G-191-380-2K2A construct, discussed in the previous chapters.
The homology modeling software module, PRIME (220–222), as available in the Maestro
software suite (223), was used for generating all the models that were later subjected
to Polak-Ribière Conjugate Gradient (PRCG) energy minimization until gradient conver-
gence using the MacroModel software module (247), also within Maestro. Molecular sur-
faces were calculated in Maestro and colored by electrostatic potential calculated from
partial charges assigned to atoms used for the calculating the surface.
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HIV/AIDS, a disease with global impact and importance, has proved to be a challenging
therapeutic target decades after discovery and extensive scientific inquiry (1, 4). The
greatest hurdle in discovering a “cure” arises from the virus’ ability to mutate, leading
to changes in molecular recognition that allow viral proteins to function normally while
evading small molecule inhbitors, thus causing drug resistance — the predominant cause
of failed anti-HIV therapy (5, 248, 249).
Targeting viral proteins alone for therapy is an almost Sisyphean task — resistance to
novel drugs often emerges during initial clinical trials, greatly diminishing the impact of
drug discovery efforts on the disease landscape (19). An alternative to investigating viral
proteins exclusively for drug discovery is to target host proteins (host factors) that inter-
act with HIV during the viral life-cycle (13, 28). Anti-HIV host factors have the distinct
advantage of side-stepping drug resistance due to mutational alteration and may prove
to be more fruitful anti-HIV drug discovery targets.
The innate immune responsemaybe triggeredby sensing of pathogen-associatedmolec-
ular patterns (PAMP) such as nucleic acids by Pattern Recognition Receptors (PRR) for
example Toll-Like Receptors (TLR). TLR3 and TLR7/8 recognize dsRNA and ssRNA respec-
tively triggering downstream signaling that leads to type 1 interferon (IFN-α/β) produc-
tion and A3G up-regulation (105). Rogue nucleic acid fragments, be they in the form of
endogenous retrotransposons (LTRs/LINE-1) or external pathogenic retroviruses (HIV-1),
pose a significant enough threat to normal functioning of eukaryotic cells that numerous
innate immune response pathways and factors that neutralize such threats have been
conserved throughout evolution.
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Role of APOBEC3 proteins APOBEC3 (A3) proteins are an important part of the host in-
nate immune response, specifically directed against genomic retroelements and retro-
viruses. Members of the human A3 subfamily of proteins have proved to be important
anti-HIV host factors that hypermutate the reverse transcribed HIV ssDNA, by deaminat-
ing Cytidines to Uridines, rendering it crippled or ineffectual (57, 117). The importance
of this class of host factors may be gauged from the fact that the HIV genome encodes
a protein, Vif (virion infectivity factor), that targets A3G and A3F to a Cul5-E3 ubiquitin
ligase complex for subsequent proteasomal degradation (76, 250). Extensive and detailed
structural data on the A3G-Vif interaction may provide the understanding required for
its disruption by small molecule ligands, and allowing A3G to impede the viral life-cycle
(13, 131, 251).
Vif is predicted to be intrinsically disordered and thus challenging to express and pu-
rify in quantities required for high-resolution structure determination. However, par-
tial structural data available in the literature (132, 137) may be used in conjunction with
homology models of Vif-binding A3 protein domains, such as A3G-NTD and A3F-CTD, to
generate testable hypotheses regarding interaction determinants. Furthermore, the re-
cent discovery of CBFβ (Core Binding Factor - beta subunit, a transcription factor) as a
novel member of the Vif-Cul5-E3 ubiquitin ligase complex is an encouraging develop-
ment, thatmay herald the discovery of new structural details relevant to Vif-A3G binding,
A3G-polyubiquitylation and subsequent proteasomal degradation (252).
Other human APOBEC3 proteins, notably A3C (253), A3H (239), and some A3A isoforms
(254) have been demonstrated to exert an anti-HIV-1 effect. The impact of these and other
APOBEC3 subfamilymembers onHIV-1warrants extensive investigation (255). The struc-
tural features of A3C have been investigated by biochemical methods and computational
models used to generate testable hypotheses on substrate binding (256, 257). Similar stud-
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ies on A3A propose the presence of specific structural features that may enable binding
to polynucleotide substrates (234).
An emerging functional role for APOBEC proteins in controlling DNAmethylation sug-
gests that the scope of this class of enzymes extends beyond the immune system to gene
expression control and genome regulation (55, 258, 259). Furthermore, since cytidine
deaminases are known to act as polynucleotide mutators (68, 166), their role in carcino-
genesis merits further investigation.
The importance of Structural data High-resolution structures of various proteins, deter-
mined over the past few decades, have proved critical in enhancing our understanding
of many aspects related to their function, such as higher-order organization (oligomer-
ization, complex formation), enzymatic action (substrate binding, enzyme chemistry, in-
hibitor binding) and regulation (post-translationalmodifications). Most importantly, such
structures have laid the foundation for an entirely new approach to drug discovery, be-
ing used as targets for in-silico docking and virtual screening to discover novel ligands.
The structures serve not only as the staring point for structure-based drug design, an ap-
proach that has led to numerous clinically useful drugs and promising drug candidates
(260–262), but when co-crystallized with ligands, enable verification of the ligand bind-
ingmodes, thus helping narrow down the search for novel chemical entities and optimiz-
ing chemical library design efforts. Data from multiple high-resolution co-crystal struc-
tures of a protein with various ligands may be useful in identifying structural features
and chemical moieties that lead to drug resistance in rapidly evolving targets, such as
employed in the case of HIV-1 protease (248, 249, 263).
The high-resolution crystal structures of A3G catalytic C-terminal domain (A3G-CTD)
have established a framework for answering various questions relating to A3G function
(147,Chapter III). Details regarding secondary structure and tertiary fold highlight the
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structural differences between A3G-CTD and human APOBEC2, the only other member of
the human APOBEC protein family with a high-resolution structure (157). The A3G-CTD
structures confirm the active site architecture is similar to known cytidine deaminases,
with a catalytically critical Zn2+ atom coordinated, in A3G-CTD, by one histidine and two
cysteine residues positioned near a catalytically essential Glutamate residue, suggesting
a shared deamination reaction mechanism (77).
The intermolecular interfaces identified from the A3G-CTD crystal structures, espe-
cially interfaces 1 and 2, may be of functional importance. Interface 1, the largest in
terms of buried surface area, is located near the active site region and a zone of positively
charged residues that coordinate a Cl− ion in the crystal structures (Chapter II). The nega-
tively charged Cl−may be incorporated as a result of the crystallization screen containing
MgCl2. However, this also suggests that a zone of positive charge near the active site re-
gion is a fundamental property of the A3G-CTD that may be functionally relevant to bind
the negatively charged phosphodiester backbone of nucleic acid substrates. Further ex-
ploration regarding the formation of this interface in solution, for example, by studying
the oligomerization propensity of interface disrupting mutants, that do not directly af-
fect structural stability, using biophysical and biochemical methods, may help establish
the functional importance of this interface.
Interface 2, the second largest observed in the A3G-CTD crystal structures, incorpo-
rates an intermolecular Zn2+ coordination site that appears specific to A3G-CTD. The Zn2+
coordination at this site is different than at the active site, with two histidine residues
contributed from the longest loop of one A3G-CTD molecule, and one cysteine residue,
on the outer surface of a helix, from the reciprocating second A3G-CTD molecule. The
Zn2+ coordinating loop is of variable length in other human A3 proteins, as seen from
the multiple sequence alignment and homology models, and may be incapable of such
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intermolecular Zn2+ coordination, thus suggesting a unique role this region may play in
defining the characteristics of each protein.
The full-length structure ofA3Gwill help answer critical questions regardingoligomer-
ization, substrate binding and activity. For example, the propensity to oligomerize pref-
erentially via the NTD or the CTDmay impact substrate binding depending on the charge
profile presented to the substrate polynucleotides. Full-length A3G has been demon-
strated to bind single-strandedDNAprimarily as oligomers, usingAtomic ForceMicroscopy
(AFM) (198). Delineating the interfacial interactions from high-resolution structures of
full-length A3G may help explain the driving force for such observations and suggest pu-
tative models for substrate binding and activity.
Drug discovery efforts In conjunction with, or even in the absence of, structure-based
drug design, high-throughput screening assays may help identify chemical entities that
bind the target protein. Co-crystal structures, of the target protein and the “hits” so
discovered, are critical to delineate the binding mode and to focus on specific chemical
classes for further investigation. The co-crystal structure of A3G-CTD,with a “hit” (MN30)
from a high-throughput assay, was solved after soaking the “apo” A3G-CTD crystals with
concentrated solutions ofMN30. The “hit” compound, MN30, binds covalently to the only
cysteine residue (C308) on the protein surface that was ’free’, i.e. not buried and not in-
volved in Zn2+ coordination. Further investigation revealed that the binding of MN30 to
another cysteine residue (C321) near the active site region underlies this inhibition, most
likely arising from steric-hinderance to substrate – ssDNA – binding. Thus structural data
from co-crystallization experiments, though providing no direct evidence of inhibitory
activity, served as a foundation for further investigation and modeling a highly probable
MN30 binding mode. Furthermore, these experiments suggest future application of this
class of compounds as molecular probes to investigate A3G and other related A3 proteins
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may be a reasonable approach.
Binding of a small molecule to a protein, such as MN30 in the case of A3G-CTD, may
interfere with not just function but also other characteristics of the protein. The covalent
modification of sulfhydryl groups on the ’free’ cysteine residues in A3G-CTD by catechol
moieties, as present in MN30, may lead to not just enzymatic inhibition but also prevent
co-crystallization of A3G-CTD incubated with MN30 by binding to C261, required for the
intermolecular Zn2+ coordinating site at interface 2, and thus hinder the formation of
crystal contacts required for crystal nucleation and growth. The final result being a lack
of co-crystals by pre-incubating A3G-CTD with MN30 and lower quality data from A3G-
CTD crystals soaked with MN30 due to possible disruption of internal crystallographic
order.
The structural mechanisms that prevent or disrupt intermolecular interactions, for
example between an enzyme and its ligand, may also be exploited for enhancing protein
activity. This is especially relevant in the case of A3G where the two forms of the protein
exist in the cell, an active lowmolecular mass (LMM) form and a dormant high molecular
mass (HMM) complex composed of A3G oligomers with RNA and other proteins (107, 108).
Drug-like small molecules that disrupt the HMM complexes so as to release A3G for pack-
aging into HIV particles are being explored further as a promising approach to exploit
the anti-retroviral effect of A3G (174, 175). The A3G-CTD structures may be used as tem-
plates for a full-length A3G homologymodel to better explore themechanism(s) of action
of such compounds.
More importantly, the attempted neutralization of A3G by Vif may not be absolute
and thus result in a background level of A3G driven hypermutations that allow a subset of
mutated viral populations to survive and eventually give rise to drug resistant HIV vari-
ants (21, 124, 264). Coupled with the error-prone viral reverse transcriptase, sublethal
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mutagenesis may contribute to the repertoire of mutations that assist HIV in escaping
anti-retroviral drugs, leading to treatment failure. In the absence of a promising strategy
to disable Vif mediated degradation of A3G and create a detriment to HIV (140, 265), ap-
proaches that inhibit sublethal mutagenesis arising from background A3G activity, may
reduce the mutational advantage available to the virus. In this context, structure-based
drug-design efforts to inhibit A3G activity may provide a useful, even if accessory, ap-
proach to removing this mutational advantage.
Future direction Structural and biophysical exploration of APOBEC3 proteins is critical
to understanding the basis of their function and to exploit their potential, by inhibition
or activation, for abrogating HIV infection. Structural data on APOBEC2 and A3G-CTD
may be used for modeling the structures of related APOBEC proteins using in-silicometh-
ods and for structure-based drug design by high-throughput virtual screening. Substrate
polynucleotides may be docked to these structures and homologymodels to gain insights
into putative binding modes and further using that information to develop novel drug-
discovery strategies. The same may also assist in designing protein constructs with mu-
tations to improve crystallization or co-crystallization outcomes.
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A reservoir-free crystallization method
1.1 Preface
The following method, based on modification of the method described in “Rayment, I.
(2002) Structure 10, 147-151.” (266), helped improve the size and diffraction quality of
A3G-CTD crystals, in conjunction with the A3G-191-380-2K2A construct, based on condi-
tions where crystals were obtained previously. The principal premise of the publication
(266) being that the nucleation and growth of protein crystals under vapor diffusion (VD)
conditions occurs under conditions that may never be precisely defined. Deviations in
micro-environmental conditions may affect the rate of VD, thus influencing transition
from nucleation promoting to growth promoting conditions in the crystallization drops.
The final concentration of reservoir solution components such as precipitant, buffer and
salt, are not identical between the drop and the reservoir during nucleation and growth,
thus crystals nucleate and grow in drop conditions that are imprecisely quantified. The
advantage to defining these condition as precisely as possible would be an improved like-
lihood of consistent crystal nucleation and growth during subsequent trials and ideally a
systematic method for improving crystal size and quality. Themethod described here is a
modified high-throughput version of the approach described in the publication referred
to above (266).
1.2 Method and Results
The high-throughput method was setup using a crystallization-tray setup robot (Phoenix
–Art Robbins Instruments, LLC) in a 96-well tray format. The primary variablewas the salt
(MgCl2) concentration, keeping the concentration of all other screen components con-
stant (12% PEG4000, 0.1 M HEPES pH 7.5) as well as the protein concentration (10 mg/mL)
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and volume (500 nL) identical in all drops. Thus, MgCl2 concentration varied across the
tray, in a non-linear fashion (Figure 1.2), whereas, the total drop volumes varied as per
the volume of screen used on a per-row basis (Figure 1.1).
The results from the above trial identified one highly favorable condition providing
a large single crystal (Figure 1.3(A)) and a small set of conditions that provided reason-
able hits (Figure 1.3(B)). The calculated effectiveMgCl2 concentration was similar, but not
identical in the drops that provided the crystals, the minor variations in concentration
were accentuated by the differences in total drop volume — perhaps a more important
variable than MgCl2 concentration alone. The majority of crystals could be harvested
and diffracted to below 2.0Å resolution under synchrotron sourced X-ray radiation.
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(A)  MgCl2 concentration(M) in screen solutions used for drop setup:
1 2 3 4 5 6 7 8 9 10 11 12
1 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
2 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
3 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
4 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
5 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
6 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
7 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
8 0.250 0.275 0.300 0.325 0.350 0.375 0.400 0.425 0.450 0.475 0.500 0.525
(B)
1 2 3 4 5 6 7 8 9 10 11 12
1 100 100 100 100 100 100 100 100 100 100 100 100
2 200 200 200 200 200 200 200 200 200 200 200 200
3 300 300 300 300 300 300 300 300 300 300 300 300
4 400 400 400 400 400 400 400 400 400 400 400 400
5 500 500 500 500 500 500 500 500 500 500 500 500
6 600 600 600 600 600 600 600 600 600 600 600 600
7 700 700 700 700 700 700 700 700 700 700 700 700
8 800 800 800 800 800 800 800 800 800 800 800 800
(C) Effective MgCl2 concentration(M) after drop setup:
1 2 3 4 5 6 7 8 9 10 11 12
1 0.0417 0.0458 0.0500 0.0542 0.0584 0.0626 0.0667 0.0709 0.0751 0.0793 0.0835 0.0877
2 0.0714 0.0786 0.0857 0.0929 0.1000 0.1072 0.1143 0.1215 0.1287 0.1358 0.1430 0.1501
3 0.0938 0.1031 0.1125 0.1219 0.1313 0.1407 0.1500 0.1594 0.1688 0.1782 0.1876 0.1970
4 0.1111 0.1222 0.1333 0.1445 0.1556 0.1667 0.1778 0.1889 0.2001 0.2112 0.2223 0.2334
5 0.1250 0.1375 0.1500 0.1625 0.1750 0.1875 0.2000 0.2125 0.2250 0.2376 0.2501 0.2626
6 0.1364 0.1500 0.1636 0.1773 0.1909 0.2046 0.2182 0.2318 0.2455 0.2591 0.2728 0.2864
7 0.1458 0.1604 0.1750 0.1896 0.2042 0.2188 0.2334 0.2479 0.2625 0.2771 0.2917 0.3063
8 0.1538 0.1692 0.1846 0.2000 0.2154 0.2308 0.2462 0.2616 0.2769 0.2923 0.3077 0.3231
Screen volume(nL)used for each drop: Protein volume is fixed in all drops (500 nL). (No reservoir.)
Figure 1.1
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Figure 1.1 : The screen is setup in a 96-well ARI INTELLI-PLATE 96-3 (Art Robbins In-
struments, LLC) and consists of 12% PEG4000, 0.1M HEPES pH 7.5 and MgCl2 varying in
concentration: (A) MgCl2 concentration is the same in each column, linearly increasing
in steps of 0.025 M. (B) the screen volume is the same in each row, increasing linearly in
steps of 100 nL. The protein (A3G-CTD at 10 mg/mL) is constant throughout the plate at
500 nL per drop. (C) Effective MgCl2 concentration varies throughout the tray as tabu-
lated. Thus, two entities that vary are : (i). MgCl2 concentration varies throughout the
plate, and (ii). the total drop volume varies across the rows. The best crystal hit obtained
with this screen occurred in the condition colored in green (see image: Figure 1.3(A)), ad-
ditional hits (but no single or as large crystals) occurred at conditions marked in yellow
(see image: Figure 1.3(B)).
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Figure 1.2 : The variation in effective MgCl2 concentration across the 96-well tray varies
in a non-linearmanner as evidenced by this colored heatmap, with concentration increas-
ing from Blue to Red. Based on data from Figure 1.1(C). Image created withMayavi2 (267).
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Figure 1.3
1.2. METHOD AND RESULTS 190
Figure 1.3 : (A) Large, single crystal obtained in the well colored green in Figure 1.1.
The two images are of the same crystal, 48 hours apart. (B)Multiple, harvestable crystals
obtained in conditions colored yellow in Figure 1.1.
191Appendix B
Additional crystal structures of A3G-191-380-2K2A
2.1 Preface
A subset of various compounds identified as A3G inhibitors in the HTS assay (Chapter
3), were used for co-crystallization by pre-incubating A3G-191-380-2K2A with these com-
pounds before setting up crystallization trials. However, no crystal hits were observed in
these trials. Subsequently, A3G-191-380-2K2A crystals, obtained using methods defined
in Appendix A, were soaked with solutions of these compounds in an attempt to obtain
structures of protein-compound complexes. Multiple X-ray diffraction datasets were ob-
tained for the soaked crystals. However, upon solving the structures, no evidence for
the presence of any of these compounds could be observed in the electron density maps.
The crystallographic data and refinement statistics for various such crystals are listed in
Figure 2.1.
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Figure 2.1 : Table summarizing the crystallographic statistics for various “apo” A3G-191-
380-2K2A crystals that diffracted and the strucutres solved. The “DatasetName” includes
the compound identifier for the compound solution that was used for soaking each crys-
tal. None of the solved structures had any electron density indicating the presence of the
soaked compound (hence “apo” crystals).
194Appendix C
In-silicomodel of the CaM + Kv channel complex
3.1 Preface
The following work was done with Dr. William Kobertz at U. Mass. Med. School. The
Kobertz lab works on ion channels, their interaction partners and methods to modulate
channel function. The crystal structures of voltage gated potassium channels (Kv) and
calcium-calmodulin (CaM) are solved, However, no known co-crystal structures or other
high-resolution structural data is available thatmay help delineate their interaction. Pre-
liminary data from experiments that tested for interaction between Kv and CaM using
polymeric hydrocarbon probes (268, 269) reveled that T34 and T110 of CaM may lie 42Å
and 52Å respectively from the “bottonm” end of the channel pore. The CaM + Kv channel
complex was modeled using these data and available crystal structure in order to better
understand this interaction.
3.2 Method and Results
The “ring” of CaM subunits (1G4Y) was docked to the rKV channel structure (2A79) by
visual inspection in PyMOL so as to prevent any clashes amongst the crystal structures. A
pseudo-atom was placed at the intracellular end of the channel pore, at a distance of 20Å
from the closest potassium ion in pore crystal structure, so as to define a region where
a chemical probe – depending on its length – may block the pore. One CaM subunit was
modeled in to satisfy distance constraints for the two Threonine residues, T34 and T110,
to the pseudo-atom, within a tolerance of ±5Å. Three other CaM subunits were generated
by symmetry operation commands within PyMOL and nudged into position to satisfy the
same distance constraints.
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The placement and orientation of CaM subunits in relation to the Kv channel could
not be unambiguously determined based on two distance constraints. The CaM subunits
could be oriented with the additional constraint that their N-termini face the intracellu-
lar end of the channel pore. Beyond these constraints, the orientation of CaM subunits
was completely ambiguous in terms of the rotational orientation of the CaM subunit “ring”
with respect to the Kv channel along the channel pore axis as in Figure 3.1 and Figure 3.3.
Similarly, the rotational orientation of each CaM subunit along its internal axes was am-
biguous andmultiple conformations could bemodeled that satisfied the twodistance con-
straints (Figure 3.1, Figure 3.2, Figure 3.3 and Figure 3.4).
The final models are being used to generate testable hypotheses and define other dis-
tance constraints to delineate the CaM + Kv channel complex interactions.
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Figure 3.1
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Figure 3.1 : CaM + rKv conformation #1 – looking up : Modeled CaM + rKv conformation
based on distance data. View looking at the channel pore from intracellular side. CaM
T34 – Magenta surface, CaM T110 – Purple surface. Pseudo-atom – Purple sphere at the
center.
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Figure 3.2
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Figure 3.2 : Modeled CaM + rKv conformation based on distance data. View looking at a
cross-section of the channel pore. Kv potassium ions – Red. CaM T34 – Magenta surface,
CaM T110 – Purple surface. Pseudo-atom – Larger purple sphere.
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Figure 3.3
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Figure 3.3 : Modeled CaM + rKv conformation based on distance data. View looking at
the channel pore from intracellular side. CaM T34 – Magenta surface, CaM T110 – Purple
surface. Pseudo-atom – Purple sphere at the center.
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Figure 3.4 : Modeled CaM + rKv conformation based on distance data. View looking at a
cross-section of the channel pore. Kv potassium ions – Red. CaM T34 – Magenta surface,
CaM T110 – Purple surface. Pseudo-atom – Larger purple sphere.
204Appendix D
Theoretical and computational analysis of HIV-1
Vif
This appendix is based in part on the paper published in
Proteins: Structure, Function, and Bioinformatics
Jared R. Auclair, Karin M. Green, Shivender Shandilya, James E. Evans, Mohan
Somasundaran, Celia A. Schiffer. (2007)Mass spectrometry analysis of HIV-1 Vif reveals
an increase in ordered structure upon oligomerization in regions necessary for viral
infectivity. Proteins: Structure, Function, and Bioinformatics 69(2):270-84. PMID: 17598142.
My contribution to this publication was the analysis of HIV-1 Vif in terms of predicted
intrinsic disorder: Figure 4.1.
4.1 Preface
HIV-1 Vif (virion infectivity factor) plays a critical role in targeting human APOBEC3G,
an anti-HIV protein, for degradation via the cellular proteasomal pathway (76). Further-
more, HIV-1 Vif is predicted to be intrinsically disordered by numerous software algo-
rithms (Figure 4.1 and Figure 4.2), a property that likely has important implications for
structure, function and biochemical properties.
4.2 Method and Results
Prior to analysis of the cross-linked HIV-1 Vif samples by MS, predictors of natural dis-
ordered regions (PONDR), was used to determine regions of intrinsic disorder in HIV-1
Vif by submitting the HXB2 HIV-1 Vif sequence (270, 271). This program uses four dif-
ferent predictor routines to suggest regions of intrinsic disorder. Only one of the four
predictors, VL-XT, predicted the N-terminus of HIV-1 Vif to be disordered, and two of the
predictors, VL-XT and XL1-XT, predicted two short regions (possibly extended loops) be-
tween residues 50–63 and 87–100 to be disordered. However, all four of the predictors,
unanimously predicted the C-terminus to be disordered (Figure 4.1). Therefore, this sug-
gests the C-terminus of HIV-1 Vif is intrinsically disordered. In addition to predicting
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regions of intrinsic disorder, HIV-1 Vif secondary structure was predicted using the Pole
BioInformatique Lyonnais Network Protein Sequence Analysis (NPS) secondary structure
consensus prediction programbecause intrinsically disordered proteins often do have de-
fined secondary structure. The majority of HIV-1 Vif secondary structure is predicted to
be random coil, however, there is predicted secondary structure: the relatively ordered
N-terminus is predicted to consist of mostly β-sheets and one α-helix and the disordered
C-terminus is predicted to consist of mostly α-helices.
The same HIV-1 Vif sequence was also submitted to FoldIndex (149) for disorder pre-
diction and correlated broadly with PONDR VL-XT predictions (Figure 4.1 and Figure 4.3).
TheMS cross-linking data when projected onto the FoldIndex predictions correlatedwith
themajority of cross-links in predicted disordered regions and few cross-links in predicted
ordered regions (Figure 4.4).
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Figure 4.1
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Figure 4.1 : Predicted regions of intrinsic disorder for HIV-1 Vif using PONDR, Predictors
of Natural Disordered Regions (270, 271). The four colors indicate four separate predictor
algorithms: blue VL3, red VL-XT, yellow XL1-XT, and green CaN-XT.
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Figure 4.2
4.2. METHOD AND RESULTS 209
Figure 4.2 : Location of HIV-1 Vif in terms of protein charge vs hydrophobicity using
PONDR, Predictors of Natural Disordered Regions (270, 271).
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Figure 4.3 : FoldIndex (149) predicted intrinsic disorder in HIV-1 Vif protein sequence
correlated with various features of Vif known from literature. Predicted secondary struc-
ture: H – α-helices and E – β-strands.
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Figure 4.4 : Mass Spectrometry data onHIV-1Vif coss-linking, from the publication listed
at the beginning of this appendix (132), was mapped onto the FoldIndex (149) predicted
intrinsic disorder in the protein sequence. All cross-linkable residues are indicated by
blue (Lysine), red (Aspartate) or purple (Glutamate) colored diamonds. Cross-links de-
duced from MS data are indicated by black, green or orange colored diamonds for Vif
monomers, dimers and trimers respectively.
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